Primary cardiac tumors, either benign or malignant, are very rare. The combined incidence is 0.002% on pooled autopsy series.¹ The benign tumors account for 63% of primary cardiac tumors and include myxoma, the most common, and followed by papillary fibroelastoma, fibroma, and hemangioma. The remaining 37% are malignant tumors, essentially predominated by sarcomas.¹

Although myxoma is the most common tumor arising in the left atrium, we present a case that shows that sarcoma can also arise from the same chamber. In fact, sarcomas could mimic cardiac myxoma.² The cardiac sarcomas can have similar clinical presentation and more importantly can share similar histopathological features. Sarcomas may have myxoid features.² Cases diagnosed as cardiac myxomas should be diligently worked up to rule out the presence of sarcomas with myxoid features. In addition, foreign bodies have been found to induce sarcomas in experimental animals.^3,4 In particular, 2 case reports have described sarcomas arising in association with Dacron vascular prostheses in humans.^5,6 We present here the case of a patient who was diagnosed with cardiac pleomorphic sarcoma 8 years after the placement of a Dacron graft.

Case presentation and summary

A 56-year-old woman with history of left atrial myxoma status after resection in 2005 and placement of a Dacron graft, morbid obesity, hypertension, and asthma presented to the emergency department with progressively worsening shortness of breath and blurry vision over period of 2 months. Acute coronary syndrome was ruled out by electrocardiogram and serial biomarkers. A computed-tomography angiogram was pursued because of her history of left atrial myxoma, and the results suggested the presence of a left atrial tumor. She underwent a transesophageal echocardiogram, which confirmed the presence of a large left atrial mass that likely was attached to the interatrial septum prolapsing across the mitral valve and was suggestive for recurrent left atrial myxoma (Figure 1). The results of a cardiac catheterization showed normal coronaries.

The patient subsequently underwent an excision of the left atrial tumor with profound internal and external myocardial cooling using antegrade blood cardioplegia under mildly hypothermic cardiopulmonary bypass. Frozen sections showed high-grade malignancy in favor of sarcoma. The hematoxylin and eosin stained permanent sections showed sheets of malignant pleomorphic spindle cells focally arranged in a storiform pattern. There were areas of necrosis and abundant mitotic activity. By immunohistochemical (IHC) stains, the tumor cells were diffusely positive for vimentin, and negative for pan-cytokeratin antibody (AE1/AE3), S-100 protein, Melan-A antibody, HMB45, CD34, CD31, myogenin, and MYOD1. IHC stains for CK-OSCAR, desmin, and smooth muscle actin were focally positive, and a ki-67 stain showed a proliferation index of about 80%. The histologic and IHC findings were consistent with a final diagnosis of high-grade undifferentiated pleomorphic sarcoma (Figure 2).

A positron emission tomography scan performed November 2013 did not show any other activity. The patient was scheduled for chemotherapy with adriamycin and ifosfamide with a plan for total of 6 cycles. Before her admission for the chemotherapy, the patient was admitted to the hospital for atrial fibrillation with rapid ventricular response and had multiple complications requiring prolonged hospitalization and rehabilitation. Repeat imaging 2 months later showed diffuse metastatic disease. However, her performance status had declined and she was not eligible for chemotherapy. She was placed under hospice care.

Discussion

This case demonstrates development of a cardiac pleomorphic sarcoma, a rare tumor, after placement of a Dacron graft. Given that foreign bodies have been found to induce sarcomas in experimental animals,^3,4 and a few case reports have described sarcomas arising in association with Dacron vascular prostheses, ^5-10 it seems that an exuberant host response around the foreign body might represent an important intermediate step in the development of the sarcoma.

There is no clearly defined pathogenesis that explains the link between a Dacron graft and sarcomas. In 1950s, Oppenheimer and colleagues described the formation of malignant tumors by various types of plastics, including Dacron, that were embedded in rats. ^3,4 Most of the tumors were some form of sarcomas. It was inferred that physical properties of the plastics may have some role in tumor development. Plastics in sheet form or film that remained in situ for more than 6 months induced significant number of tumors compared with other forms such as sponges, films with holes, or powders.^3,4 The 3-dimensional polymeric structure of the Dacron graft seems to play a role in induction of sarcoma as well. A pore diameter of less than 0.4 mm may increase tumorigenicity.¹¹ The removal of the material before the 6-month mark does not lead to malignant tumors, which further supports the link between Dacron graft and formation of tumor. A pocket is formed around the foreign material after a certain period, as has been shown in histologic studies as the site of tumor origin.^9,10

At the molecular level, the MDM-2/p53 pathway has been cited as possible mechanism for pathogenesis of intimal sarcoma.^12,13 It has been suggested that endothelial dysplasia occurs as a precursor lesion in these sarcomas.¹⁴ The Dacron graft may cause a dysplastic effect on the endothelium leading to this precursor lesion and in certain cases transforming into sarcoma. Further definitive studies are required.

The primary treatment for cardiac sarcoma is surgical removal, although it is not always feasible. Findings in a Mayo clinic study showed that the median survival was 17 months for patients who underwent complete surgical excision, compared with 6 months for those who complete resection was not possible.¹⁵ In addition, a 10% survival rate at 1 year has been reported in primary cardiac sarcomas that are treated without any type of surgery.¹⁶

There is no clear-cut evidence supporting or refuting adjuvant chemotherapy for cardiac sarcoma. Some have inferred a potential benefit of adjuvant chemotherapy although definitive conclusions cannot be drawn. The median survival was 16.5 months in a case series of patients who received adjuvant chemotherapy, compared with 9 months and 11 months in 2 other case series.^17,18,19 Multiple chemotherapy regimens have been used in the past for treatment. A retrospective study by Llombart-Cussac colleagues, analyzed 15 patients who had received doxorubicin-containing chemotherapy, in most cases combined with ifosfamide or dacarbazine. ²⁰ Resection was complete in 6 patients and incomplete in 9. The patients were given chemotherapy within 6 weeks of surgery. Five patients developed metastatic disease during therapy. The median interval to first relapse was 10 months and overall median survival was 12 months in these patients.²⁰ Other regimens that have been used for treatment are mitomycin, doxorubicin, and cisplatin (MAP); doxorubicine, cyclophosphamide, and vincristine (DCV); ifosfamide and etoposide (IE); ifostamide, doxorubicin, and decarbazine; doxorubicin and paclitaxel, and paclitaxel alone.⁴ Of those, a patient with on the IE survived the longest, 32 months.

Radiation showed some benefit in progression-free survival in a French retrospective study.²¹ Radiation therapies have been tried in other cases, as well in addition to chemotherapy. However, there is not enough data to support or refute it at this time.^15,17,20 Several sporadic cases reported show benefit of cardiac transplantation.^21,22

Conclusion

In consideration of the placement of the Dacron graft 8 years before the tumor occurrence, the anatomic proximity of the tumor to the Dacron graft, and the association between sarcoma with Dacron in medical literature, it seems logical to infer that this unusual malignancy in our patient is associated with the Dacron prosthesis. TSJ

Correspondence

1. Patil HR, Singh D, Hajdu M. Cardiac sarcoma presenting as heart failure and diagnosed as recurrent myxoma by echocardiogram. Eur J Echocardiogr. 2010;11(4):E12.

2. Awamleh P, Alberca MT, Gamallo C, Enrech S, Sarraj A. Left atrium myxosarcoma: an exceptional cardiac malignant primary tumor. Clin Cardiol. 2007;30(6):306-308.

3. Oppenheimer BS, Oppenheimer ET, Stout AP, Danishefsky I. Malignant tumors resulting from embedding plastics in rodents. Science. 1953;118:305-306.

4. Oppenheimer BS, Oppenheimer ET, Stout AP, Willhite M, Danishefski, I. The latent period in carcinogenesis by plastics in rats and its relation to the presarcomatous stage. Cancer. 1958;11(1):204-213.

5. Almeida NJ, Hoang P, Biddle P, Arouni A, Esterbrooks D. Primary cardiac angiosarcoma: in a patient with a Dacron aortic prosthesis. Tex Heart Inst J. 2011;38(1):61-65; discussion 65.

6. Stewart B, Manglik N, Zhao B, et al. Aortic intimal sarcoma: report of two cases with immunohistochemical analysis for pathogenesis. Cardiovasc Pathol. 2013;22(5):351-356.

7. Umscheid TW, Rouhani G, Morlang T, et al. Hemangiosarcoma after endovascular aortic aneurysm repair. J Endovasc Ther. 2007;14(1):101-105. 

8. Ben-Izhak O, Vlodavsky E, Ofer A, Engel A, Nitecky S, Hoffman A. Epithelioid angiosarcoma associated with a Dacron vascular graft. Am J Surg Pathol. 1999;23(11):1418-1422. 

9. Fyfe BS, Quintana CS, Kaneko M, Griepp RB. Aortic sarcoma four years after Dacron graft insertion. Ann Thorac Surg. 1994;58(6):1752-1754. 

10. O’Connell TX, Fee HJ, Golding A. Sarcoma associated with Dacron prosthetic material: case report and review of the literature. J Thorac Cardiovasc Surg. 1976;72(1):94-96.

11. Karp RD, Johnson KH, Buoen LC, et al. Tumorogenesis by millipore filters in mice: histology and ultastructure of tissue reactions, as related to pore size. J Natl Cancer Inst. 1973;51:1275-1285.

12. Bode-Lesniewska B, Zhao J, Speel EJ, et al. Gains of 12q13-14 and overexpression of mdm2 are frequent findings in intimal sarcomas of the pulmonary artery. Virchows Arch. 2001;438:57-65.

13. Zeitz C, Rossle M, Haas C, et al. MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am J Surg Pathol. 1998;153:1425-1433.

14. Haber LM, Truong L. Immunohistochemical demonstration of the endothelialnature of aortic intimal sarcoma. Am J Surg Pathol. 1988 Oct;12(10):798-802. PubMed PMID: 3138923.

15. Simpson L, Kumar SK, Okuno SH, et al. Malignant primary cardiac tumors: review of a single institution experience. Cancer. 2008;112(11):2440-2446.

16. Leja MJ, Shah DJ, Reardon MJ. Primary cardiac tumors. Tex Heart Inst J. 2011;38(3):261-262.

17. Donsbeck AV, Ranchere D, Coindre JM, Le Gall F, Cordier JF, Loire R. Primary cardiac sarcomas: an immunohistochemical and grading study with long-term follow-up of 24 cases. Histopathology. 1999;34(4):295-304.

18. Putnam JB, Sweeney MS, Colon R, Lanza LA, Frazier OH, Cooley DC. Primary cardiac sarcomas. Ann Thorac Surg. 1990; 51; 906-910.

19. Murphy WR, Sweeney MS, Putnam JB et al. Surgical treatment of cardiac tumors: a 25-year experience. Ann Thorac Surg. 1990;49;612-618.

20. Llombart-Cussac A, Pivot X, Contesso G, et al. Adjuvant chemotherapy for primary cardiac sarcomas: the IGR experience. Br J Cancer. 1998;78(12):1624-1628.

21. Isambert N, Ray-Coquard I, Italiano A, et al. Primary cardiac sarcomas: a retrospective study of the French Sarcoma Group. Eur J Cancer. 2014;50(1):128-136.

22. Agaimy A, Rösch J, Weyand M, Strecker T. Primary and metastatic cardiac sarcomas: a 12-year experience at a German heart center. Int J Clin Exp Pathol. 2012;5(9):928-938.

Primary cardiac tumors, either benign or malignant, are very rare. The combined incidence is 0.002% on pooled autopsy series.¹ The benign tumors account for 63% of primary cardiac tumors and include myxoma, the most common, and followed by papillary fibroelastoma, fibroma, and hemangioma. The remaining 37% are malignant tumors, essentially predominated by sarcomas.¹

Although myxoma is the most common tumor arising in the left atrium, we present a case that shows that sarcoma can also arise from the same chamber. In fact, sarcomas could mimic cardiac myxoma.² The cardiac sarcomas can have similar clinical presentation and more importantly can share similar histopathological features. Sarcomas may have myxoid features.² Cases diagnosed as cardiac myxomas should be diligently worked up to rule out the presence of sarcomas with myxoid features. In addition, foreign bodies have been found to induce sarcomas in experimental animals.^3,4 In particular, 2 case reports have described sarcomas arising in association with Dacron vascular prostheses in humans.^5,6 We present here the case of a patient who was diagnosed with cardiac pleomorphic sarcoma 8 years after the placement of a Dacron graft.

Case presentation and summary

A 56-year-old woman with history of left atrial myxoma status after resection in 2005 and placement of a Dacron graft, morbid obesity, hypertension, and asthma presented to the emergency department with progressively worsening shortness of breath and blurry vision over period of 2 months. Acute coronary syndrome was ruled out by electrocardiogram and serial biomarkers. A computed-tomography angiogram was pursued because of her history of left atrial myxoma, and the results suggested the presence of a left atrial tumor. She underwent a transesophageal echocardiogram, which confirmed the presence of a large left atrial mass that likely was attached to the interatrial septum prolapsing across the mitral valve and was suggestive for recurrent left atrial myxoma (Figure 1). The results of a cardiac catheterization showed normal coronaries.

The patient subsequently underwent an excision of the left atrial tumor with profound internal and external myocardial cooling using antegrade blood cardioplegia under mildly hypothermic cardiopulmonary bypass. Frozen sections showed high-grade malignancy in favor of sarcoma. The hematoxylin and eosin stained permanent sections showed sheets of malignant pleomorphic spindle cells focally arranged in a storiform pattern. There were areas of necrosis and abundant mitotic activity. By immunohistochemical (IHC) stains, the tumor cells were diffusely positive for vimentin, and negative for pan-cytokeratin antibody (AE1/AE3), S-100 protein, Melan-A antibody, HMB45, CD34, CD31, myogenin, and MYOD1. IHC stains for CK-OSCAR, desmin, and smooth muscle actin were focally positive, and a ki-67 stain showed a proliferation index of about 80%. The histologic and IHC findings were consistent with a final diagnosis of high-grade undifferentiated pleomorphic sarcoma (Figure 2).

A positron emission tomography scan performed November 2013 did not show any other activity. The patient was scheduled for chemotherapy with adriamycin and ifosfamide with a plan for total of 6 cycles. Before her admission for the chemotherapy, the patient was admitted to the hospital for atrial fibrillation with rapid ventricular response and had multiple complications requiring prolonged hospitalization and rehabilitation. Repeat imaging 2 months later showed diffuse metastatic disease. However, her performance status had declined and she was not eligible for chemotherapy. She was placed under hospice care.

Discussion

This case demonstrates development of a cardiac pleomorphic sarcoma, a rare tumor, after placement of a Dacron graft. Given that foreign bodies have been found to induce sarcomas in experimental animals,^3,4 and a few case reports have described sarcomas arising in association with Dacron vascular prostheses, ^5-10 it seems that an exuberant host response around the foreign body might represent an important intermediate step in the development of the sarcoma.

There is no clearly defined pathogenesis that explains the link between a Dacron graft and sarcomas. In 1950s, Oppenheimer and colleagues described the formation of malignant tumors by various types of plastics, including Dacron, that were embedded in rats. ^3,4 Most of the tumors were some form of sarcomas. It was inferred that physical properties of the plastics may have some role in tumor development. Plastics in sheet form or film that remained in situ for more than 6 months induced significant number of tumors compared with other forms such as sponges, films with holes, or powders.^3,4 The 3-dimensional polymeric structure of the Dacron graft seems to play a role in induction of sarcoma as well. A pore diameter of less than 0.4 mm may increase tumorigenicity.¹¹ The removal of the material before the 6-month mark does not lead to malignant tumors, which further supports the link between Dacron graft and formation of tumor. A pocket is formed around the foreign material after a certain period, as has been shown in histologic studies as the site of tumor origin.^9,10

At the molecular level, the MDM-2/p53 pathway has been cited as possible mechanism for pathogenesis of intimal sarcoma.^12,13 It has been suggested that endothelial dysplasia occurs as a precursor lesion in these sarcomas.¹⁴ The Dacron graft may cause a dysplastic effect on the endothelium leading to this precursor lesion and in certain cases transforming into sarcoma. Further definitive studies are required.

The primary treatment for cardiac sarcoma is surgical removal, although it is not always feasible. Findings in a Mayo clinic study showed that the median survival was 17 months for patients who underwent complete surgical excision, compared with 6 months for those who complete resection was not possible.¹⁵ In addition, a 10% survival rate at 1 year has been reported in primary cardiac sarcomas that are treated without any type of surgery.¹⁶

There is no clear-cut evidence supporting or refuting adjuvant chemotherapy for cardiac sarcoma. Some have inferred a potential benefit of adjuvant chemotherapy although definitive conclusions cannot be drawn. The median survival was 16.5 months in a case series of patients who received adjuvant chemotherapy, compared with 9 months and 11 months in 2 other case series.^17,18,19 Multiple chemotherapy regimens have been used in the past for treatment. A retrospective study by Llombart-Cussac colleagues, analyzed 15 patients who had received doxorubicin-containing chemotherapy, in most cases combined with ifosfamide or dacarbazine. ²⁰ Resection was complete in 6 patients and incomplete in 9. The patients were given chemotherapy within 6 weeks of surgery. Five patients developed metastatic disease during therapy. The median interval to first relapse was 10 months and overall median survival was 12 months in these patients.²⁰ Other regimens that have been used for treatment are mitomycin, doxorubicin, and cisplatin (MAP); doxorubicine, cyclophosphamide, and vincristine (DCV); ifosfamide and etoposide (IE); ifostamide, doxorubicin, and decarbazine; doxorubicin and paclitaxel, and paclitaxel alone.⁴ Of those, a patient with on the IE survived the longest, 32 months.

Radiation showed some benefit in progression-free survival in a French retrospective study.²¹ Radiation therapies have been tried in other cases, as well in addition to chemotherapy. However, there is not enough data to support or refute it at this time.^15,17,20 Several sporadic cases reported show benefit of cardiac transplantation.^21,22

Conclusion

In consideration of the placement of the Dacron graft 8 years before the tumor occurrence, the anatomic proximity of the tumor to the Dacron graft, and the association between sarcoma with Dacron in medical literature, it seems logical to infer that this unusual malignancy in our patient is associated with the Dacron prosthesis. TSJ

Correspondence

1. Patil HR, Singh D, Hajdu M. Cardiac sarcoma presenting as heart failure and diagnosed as recurrent myxoma by echocardiogram. Eur J Echocardiogr. 2010;11(4):E12.

2. Awamleh P, Alberca MT, Gamallo C, Enrech S, Sarraj A. Left atrium myxosarcoma: an exceptional cardiac malignant primary tumor. Clin Cardiol. 2007;30(6):306-308.

3. Oppenheimer BS, Oppenheimer ET, Stout AP, Danishefsky I. Malignant tumors resulting from embedding plastics in rodents. Science. 1953;118:305-306.

4. Oppenheimer BS, Oppenheimer ET, Stout AP, Willhite M, Danishefski, I. The latent period in carcinogenesis by plastics in rats and its relation to the presarcomatous stage. Cancer. 1958;11(1):204-213.

5. Almeida NJ, Hoang P, Biddle P, Arouni A, Esterbrooks D. Primary cardiac angiosarcoma: in a patient with a Dacron aortic prosthesis. Tex Heart Inst J. 2011;38(1):61-65; discussion 65.

6. Stewart B, Manglik N, Zhao B, et al. Aortic intimal sarcoma: report of two cases with immunohistochemical analysis for pathogenesis. Cardiovasc Pathol. 2013;22(5):351-356.

7. Umscheid TW, Rouhani G, Morlang T, et al. Hemangiosarcoma after endovascular aortic aneurysm repair. J Endovasc Ther. 2007;14(1):101-105. 

8. Ben-Izhak O, Vlodavsky E, Ofer A, Engel A, Nitecky S, Hoffman A. Epithelioid angiosarcoma associated with a Dacron vascular graft. Am J Surg Pathol. 1999;23(11):1418-1422. 

9. Fyfe BS, Quintana CS, Kaneko M, Griepp RB. Aortic sarcoma four years after Dacron graft insertion. Ann Thorac Surg. 1994;58(6):1752-1754. 

10. O’Connell TX, Fee HJ, Golding A. Sarcoma associated with Dacron prosthetic material: case report and review of the literature. J Thorac Cardiovasc Surg. 1976;72(1):94-96.

11. Karp RD, Johnson KH, Buoen LC, et al. Tumorogenesis by millipore filters in mice: histology and ultastructure of tissue reactions, as related to pore size. J Natl Cancer Inst. 1973;51:1275-1285.

12. Bode-Lesniewska B, Zhao J, Speel EJ, et al. Gains of 12q13-14 and overexpression of mdm2 are frequent findings in intimal sarcomas of the pulmonary artery. Virchows Arch. 2001;438:57-65.

13. Zeitz C, Rossle M, Haas C, et al. MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am J Surg Pathol. 1998;153:1425-1433.

14. Haber LM, Truong L. Immunohistochemical demonstration of the endothelialnature of aortic intimal sarcoma. Am J Surg Pathol. 1988 Oct;12(10):798-802. PubMed PMID: 3138923.

15. Simpson L, Kumar SK, Okuno SH, et al. Malignant primary cardiac tumors: review of a single institution experience. Cancer. 2008;112(11):2440-2446.

16. Leja MJ, Shah DJ, Reardon MJ. Primary cardiac tumors. Tex Heart Inst J. 2011;38(3):261-262.

17. Donsbeck AV, Ranchere D, Coindre JM, Le Gall F, Cordier JF, Loire R. Primary cardiac sarcomas: an immunohistochemical and grading study with long-term follow-up of 24 cases. Histopathology. 1999;34(4):295-304.

18. Putnam JB, Sweeney MS, Colon R, Lanza LA, Frazier OH, Cooley DC. Primary cardiac sarcomas. Ann Thorac Surg. 1990; 51; 906-910.

19. Murphy WR, Sweeney MS, Putnam JB et al. Surgical treatment of cardiac tumors: a 25-year experience. Ann Thorac Surg. 1990;49;612-618.

20. Llombart-Cussac A, Pivot X, Contesso G, et al. Adjuvant chemotherapy for primary cardiac sarcomas: the IGR experience. Br J Cancer. 1998;78(12):1624-1628.

21. Isambert N, Ray-Coquard I, Italiano A, et al. Primary cardiac sarcomas: a retrospective study of the French Sarcoma Group. Eur J Cancer. 2014;50(1):128-136.

22. Agaimy A, Rösch J, Weyand M, Strecker T. Primary and metastatic cardiac sarcomas: a 12-year experience at a German heart center. Int J Clin Exp Pathol. 2012;5(9):928-938.

Primary cardiac tumors, either benign or malignant, are very rare. The combined incidence is 0.002% on pooled autopsy series.¹ The benign tumors account for 63% of primary cardiac tumors and include myxoma, the most common, and followed by papillary fibroelastoma, fibroma, and hemangioma. The remaining 37% are malignant tumors, essentially predominated by sarcomas.¹

Although myxoma is the most common tumor arising in the left atrium, we present a case that shows that sarcoma can also arise from the same chamber. In fact, sarcomas could mimic cardiac myxoma.² The cardiac sarcomas can have similar clinical presentation and more importantly can share similar histopathological features. Sarcomas may have myxoid features.² Cases diagnosed as cardiac myxomas should be diligently worked up to rule out the presence of sarcomas with myxoid features. In addition, foreign bodies have been found to induce sarcomas in experimental animals.^3,4 In particular, 2 case reports have described sarcomas arising in association with Dacron vascular prostheses in humans.^5,6 We present here the case of a patient who was diagnosed with cardiac pleomorphic sarcoma 8 years after the placement of a Dacron graft.

Case presentation and summary

A 56-year-old woman with history of left atrial myxoma status after resection in 2005 and placement of a Dacron graft, morbid obesity, hypertension, and asthma presented to the emergency department with progressively worsening shortness of breath and blurry vision over period of 2 months. Acute coronary syndrome was ruled out by electrocardiogram and serial biomarkers. A computed-tomography angiogram was pursued because of her history of left atrial myxoma, and the results suggested the presence of a left atrial tumor. She underwent a transesophageal echocardiogram, which confirmed the presence of a large left atrial mass that likely was attached to the interatrial septum prolapsing across the mitral valve and was suggestive for recurrent left atrial myxoma (Figure 1). The results of a cardiac catheterization showed normal coronaries.

The patient subsequently underwent an excision of the left atrial tumor with profound internal and external myocardial cooling using antegrade blood cardioplegia under mildly hypothermic cardiopulmonary bypass. Frozen sections showed high-grade malignancy in favor of sarcoma. The hematoxylin and eosin stained permanent sections showed sheets of malignant pleomorphic spindle cells focally arranged in a storiform pattern. There were areas of necrosis and abundant mitotic activity. By immunohistochemical (IHC) stains, the tumor cells were diffusely positive for vimentin, and negative for pan-cytokeratin antibody (AE1/AE3), S-100 protein, Melan-A antibody, HMB45, CD34, CD31, myogenin, and MYOD1. IHC stains for CK-OSCAR, desmin, and smooth muscle actin were focally positive, and a ki-67 stain showed a proliferation index of about 80%. The histologic and IHC findings were consistent with a final diagnosis of high-grade undifferentiated pleomorphic sarcoma (Figure 2).

A positron emission tomography scan performed November 2013 did not show any other activity. The patient was scheduled for chemotherapy with adriamycin and ifosfamide with a plan for total of 6 cycles. Before her admission for the chemotherapy, the patient was admitted to the hospital for atrial fibrillation with rapid ventricular response and had multiple complications requiring prolonged hospitalization and rehabilitation. Repeat imaging 2 months later showed diffuse metastatic disease. However, her performance status had declined and she was not eligible for chemotherapy. She was placed under hospice care.

Discussion

This case demonstrates development of a cardiac pleomorphic sarcoma, a rare tumor, after placement of a Dacron graft. Given that foreign bodies have been found to induce sarcomas in experimental animals,^3,4 and a few case reports have described sarcomas arising in association with Dacron vascular prostheses, ^5-10 it seems that an exuberant host response around the foreign body might represent an important intermediate step in the development of the sarcoma.

There is no clearly defined pathogenesis that explains the link between a Dacron graft and sarcomas. In 1950s, Oppenheimer and colleagues described the formation of malignant tumors by various types of plastics, including Dacron, that were embedded in rats. ^3,4 Most of the tumors were some form of sarcomas. It was inferred that physical properties of the plastics may have some role in tumor development. Plastics in sheet form or film that remained in situ for more than 6 months induced significant number of tumors compared with other forms such as sponges, films with holes, or powders.^3,4 The 3-dimensional polymeric structure of the Dacron graft seems to play a role in induction of sarcoma as well. A pore diameter of less than 0.4 mm may increase tumorigenicity.¹¹ The removal of the material before the 6-month mark does not lead to malignant tumors, which further supports the link between Dacron graft and formation of tumor. A pocket is formed around the foreign material after a certain period, as has been shown in histologic studies as the site of tumor origin.^9,10

At the molecular level, the MDM-2/p53 pathway has been cited as possible mechanism for pathogenesis of intimal sarcoma.^12,13 It has been suggested that endothelial dysplasia occurs as a precursor lesion in these sarcomas.¹⁴ The Dacron graft may cause a dysplastic effect on the endothelium leading to this precursor lesion and in certain cases transforming into sarcoma. Further definitive studies are required.

The primary treatment for cardiac sarcoma is surgical removal, although it is not always feasible. Findings in a Mayo clinic study showed that the median survival was 17 months for patients who underwent complete surgical excision, compared with 6 months for those who complete resection was not possible.¹⁵ In addition, a 10% survival rate at 1 year has been reported in primary cardiac sarcomas that are treated without any type of surgery.¹⁶

There is no clear-cut evidence supporting or refuting adjuvant chemotherapy for cardiac sarcoma. Some have inferred a potential benefit of adjuvant chemotherapy although definitive conclusions cannot be drawn. The median survival was 16.5 months in a case series of patients who received adjuvant chemotherapy, compared with 9 months and 11 months in 2 other case series.^17,18,19 Multiple chemotherapy regimens have been used in the past for treatment. A retrospective study by Llombart-Cussac colleagues, analyzed 15 patients who had received doxorubicin-containing chemotherapy, in most cases combined with ifosfamide or dacarbazine. ²⁰ Resection was complete in 6 patients and incomplete in 9. The patients were given chemotherapy within 6 weeks of surgery. Five patients developed metastatic disease during therapy. The median interval to first relapse was 10 months and overall median survival was 12 months in these patients.²⁰ Other regimens that have been used for treatment are mitomycin, doxorubicin, and cisplatin (MAP); doxorubicine, cyclophosphamide, and vincristine (DCV); ifosfamide and etoposide (IE); ifostamide, doxorubicin, and decarbazine; doxorubicin and paclitaxel, and paclitaxel alone.⁴ Of those, a patient with on the IE survived the longest, 32 months.

Radiation showed some benefit in progression-free survival in a French retrospective study.²¹ Radiation therapies have been tried in other cases, as well in addition to chemotherapy. However, there is not enough data to support or refute it at this time.^15,17,20 Several sporadic cases reported show benefit of cardiac transplantation.^21,22

Conclusion

In consideration of the placement of the Dacron graft 8 years before the tumor occurrence, the anatomic proximity of the tumor to the Dacron graft, and the association between sarcoma with Dacron in medical literature, it seems logical to infer that this unusual malignancy in our patient is associated with the Dacron prosthesis. TSJ

Correspondence

1. Patil HR, Singh D, Hajdu M. Cardiac sarcoma presenting as heart failure and diagnosed as recurrent myxoma by echocardiogram. Eur J Echocardiogr. 2010;11(4):E12.

2. Awamleh P, Alberca MT, Gamallo C, Enrech S, Sarraj A. Left atrium myxosarcoma: an exceptional cardiac malignant primary tumor. Clin Cardiol. 2007;30(6):306-308.

3. Oppenheimer BS, Oppenheimer ET, Stout AP, Danishefsky I. Malignant tumors resulting from embedding plastics in rodents. Science. 1953;118:305-306.

4. Oppenheimer BS, Oppenheimer ET, Stout AP, Willhite M, Danishefski, I. The latent period in carcinogenesis by plastics in rats and its relation to the presarcomatous stage. Cancer. 1958;11(1):204-213.

5. Almeida NJ, Hoang P, Biddle P, Arouni A, Esterbrooks D. Primary cardiac angiosarcoma: in a patient with a Dacron aortic prosthesis. Tex Heart Inst J. 2011;38(1):61-65; discussion 65.

6. Stewart B, Manglik N, Zhao B, et al. Aortic intimal sarcoma: report of two cases with immunohistochemical analysis for pathogenesis. Cardiovasc Pathol. 2013;22(5):351-356.

7. Umscheid TW, Rouhani G, Morlang T, et al. Hemangiosarcoma after endovascular aortic aneurysm repair. J Endovasc Ther. 2007;14(1):101-105. 

8. Ben-Izhak O, Vlodavsky E, Ofer A, Engel A, Nitecky S, Hoffman A. Epithelioid angiosarcoma associated with a Dacron vascular graft. Am J Surg Pathol. 1999;23(11):1418-1422. 

9. Fyfe BS, Quintana CS, Kaneko M, Griepp RB. Aortic sarcoma four years after Dacron graft insertion. Ann Thorac Surg. 1994;58(6):1752-1754. 

10. O’Connell TX, Fee HJ, Golding A. Sarcoma associated with Dacron prosthetic material: case report and review of the literature. J Thorac Cardiovasc Surg. 1976;72(1):94-96.

11. Karp RD, Johnson KH, Buoen LC, et al. Tumorogenesis by millipore filters in mice: histology and ultastructure of tissue reactions, as related to pore size. J Natl Cancer Inst. 1973;51:1275-1285.

12. Bode-Lesniewska B, Zhao J, Speel EJ, et al. Gains of 12q13-14 and overexpression of mdm2 are frequent findings in intimal sarcomas of the pulmonary artery. Virchows Arch. 2001;438:57-65.

13. Zeitz C, Rossle M, Haas C, et al. MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am J Surg Pathol. 1998;153:1425-1433.

14. Haber LM, Truong L. Immunohistochemical demonstration of the endothelialnature of aortic intimal sarcoma. Am J Surg Pathol. 1988 Oct;12(10):798-802. PubMed PMID: 3138923.

15. Simpson L, Kumar SK, Okuno SH, et al. Malignant primary cardiac tumors: review of a single institution experience. Cancer. 2008;112(11):2440-2446.

16. Leja MJ, Shah DJ, Reardon MJ. Primary cardiac tumors. Tex Heart Inst J. 2011;38(3):261-262.

17. Donsbeck AV, Ranchere D, Coindre JM, Le Gall F, Cordier JF, Loire R. Primary cardiac sarcomas: an immunohistochemical and grading study with long-term follow-up of 24 cases. Histopathology. 1999;34(4):295-304.

18. Putnam JB, Sweeney MS, Colon R, Lanza LA, Frazier OH, Cooley DC. Primary cardiac sarcomas. Ann Thorac Surg. 1990; 51; 906-910.

19. Murphy WR, Sweeney MS, Putnam JB et al. Surgical treatment of cardiac tumors: a 25-year experience. Ann Thorac Surg. 1990;49;612-618.

20. Llombart-Cussac A, Pivot X, Contesso G, et al. Adjuvant chemotherapy for primary cardiac sarcomas: the IGR experience. Br J Cancer. 1998;78(12):1624-1628.

21. Isambert N, Ray-Coquard I, Italiano A, et al. Primary cardiac sarcomas: a retrospective study of the French Sarcoma Group. Eur J Cancer. 2014;50(1):128-136.

22. Agaimy A, Rösch J, Weyand M, Strecker T. Primary and metastatic cardiac sarcomas: a 12-year experience at a German heart center. Int J Clin Exp Pathol. 2012;5(9):928-938.

A new review of the literature on chronic venous insufficiency in pregnant women reveals considerable guidance for their treatment. CVI occurs in up to 80% of pregnant women, while around 7 of every 1,000 pregnant mothers face venous thromboembolism and pulmonary embolism.

As reported in the March edition of the Journal of Vascular Surgery: Venous and Lymphatic Disorders, clinicians from Johns Hopkins Hospital and the Greater Baltimore Medical Center led by vascular surgeon Dr. Jennifer Heller, analyzed 80 studies related to pregnancy, VTE and CVI.

Pregnancy causes significant hemodynamic changes within the circulatory system.  While these are considered essential for the health of the developing fetus, the changes place considerable stress on the expectant mother’s heart and lower extremity veins. 

Chronic venous insufficiency (CVI), marked by varicose veins, pain, edema, itching, skin discoloration, night cramps and heaviness are all common, particularly during the third trimester.  Venous thromboembolism (VTE) and pulmonary embolism (PE) affects pregnant women nearly five times more than non-pregnant women.  In fact, VTE is the number one cause of maternal death in developing countries.

With regards to the hemodynamic and physiologic changes, the review reveals pregnancy:

• Decreases systemic vascular resistance
• Increases heart rate
• Increases cardiac output
• Decreases deep venous blood flow
• Increases deep vein diameters, and
• Induces a hypercoagulable state

Treatment strategies for primary CVI in pregnancy, which occurs in up to 80% of women, were reviewed and include indications for non-pharmacologic therapies (compression, reflexology, water emersion), and pharmacologic treatments (non-steroidal anti-inflammatory drugs, fondaparinux, and low-molecular-weight heparin).

With an incidence up to 7 per 1,000 pregnancies, acute VTE remains an important issue in pregnancy.  The authors provided a thorough review of VTE prevention during pregnancy, and VTE treatment during pregnancy (including indications for caval filters and management of iliofemoral thrombosis).

“It is important for physicians to comprehend the full extent of the hemodynamic factors that contribute to the increased risk of lower extremity venous disease as well as the most appropriate and effective evidence-based management options,” stated Dr. Heller.  “While prophylaxis and treatment of VTE has been extensively studied in pregnancy, further research is required to look at the potential effectiveness and long-term safety profiles of new oral anticoagulants in the mother and fetus.” 

She also hopes that future randomized trials will evaluate treatment strategies to relieve symptoms associated with chronic venous insufficiency during pregnancy.

Complete understanding of these issues helps physicians prepare their patients for these eventualities during pregnancy and treat venous complications effectively. 

To download the complete article, open access through April 30, click here.  

A new review of the literature on chronic venous insufficiency in pregnant women reveals considerable guidance for their treatment. CVI occurs in up to 80% of pregnant women, while around 7 of every 1,000 pregnant mothers face venous thromboembolism and pulmonary embolism.

As reported in the March edition of the Journal of Vascular Surgery: Venous and Lymphatic Disorders, clinicians from Johns Hopkins Hospital and the Greater Baltimore Medical Center led by vascular surgeon Dr. Jennifer Heller, analyzed 80 studies related to pregnancy, VTE and CVI.

Pregnancy causes significant hemodynamic changes within the circulatory system.  While these are considered essential for the health of the developing fetus, the changes place considerable stress on the expectant mother’s heart and lower extremity veins. 

Chronic venous insufficiency (CVI), marked by varicose veins, pain, edema, itching, skin discoloration, night cramps and heaviness are all common, particularly during the third trimester.  Venous thromboembolism (VTE) and pulmonary embolism (PE) affects pregnant women nearly five times more than non-pregnant women.  In fact, VTE is the number one cause of maternal death in developing countries.

With regards to the hemodynamic and physiologic changes, the review reveals pregnancy:

• Decreases systemic vascular resistance
• Increases heart rate
• Increases cardiac output
• Decreases deep venous blood flow
• Increases deep vein diameters, and
• Induces a hypercoagulable state

Treatment strategies for primary CVI in pregnancy, which occurs in up to 80% of women, were reviewed and include indications for non-pharmacologic therapies (compression, reflexology, water emersion), and pharmacologic treatments (non-steroidal anti-inflammatory drugs, fondaparinux, and low-molecular-weight heparin).

With an incidence up to 7 per 1,000 pregnancies, acute VTE remains an important issue in pregnancy.  The authors provided a thorough review of VTE prevention during pregnancy, and VTE treatment during pregnancy (including indications for caval filters and management of iliofemoral thrombosis).

“It is important for physicians to comprehend the full extent of the hemodynamic factors that contribute to the increased risk of lower extremity venous disease as well as the most appropriate and effective evidence-based management options,” stated Dr. Heller.  “While prophylaxis and treatment of VTE has been extensively studied in pregnancy, further research is required to look at the potential effectiveness and long-term safety profiles of new oral anticoagulants in the mother and fetus.” 

She also hopes that future randomized trials will evaluate treatment strategies to relieve symptoms associated with chronic venous insufficiency during pregnancy.

Complete understanding of these issues helps physicians prepare their patients for these eventualities during pregnancy and treat venous complications effectively. 

To download the complete article, open access through April 30, click here.  

A new review of the literature on chronic venous insufficiency in pregnant women reveals considerable guidance for their treatment. CVI occurs in up to 80% of pregnant women, while around 7 of every 1,000 pregnant mothers face venous thromboembolism and pulmonary embolism.

As reported in the March edition of the Journal of Vascular Surgery: Venous and Lymphatic Disorders, clinicians from Johns Hopkins Hospital and the Greater Baltimore Medical Center led by vascular surgeon Dr. Jennifer Heller, analyzed 80 studies related to pregnancy, VTE and CVI.

Pregnancy causes significant hemodynamic changes within the circulatory system.  While these are considered essential for the health of the developing fetus, the changes place considerable stress on the expectant mother’s heart and lower extremity veins. 

Chronic venous insufficiency (CVI), marked by varicose veins, pain, edema, itching, skin discoloration, night cramps and heaviness are all common, particularly during the third trimester.  Venous thromboembolism (VTE) and pulmonary embolism (PE) affects pregnant women nearly five times more than non-pregnant women.  In fact, VTE is the number one cause of maternal death in developing countries.

With regards to the hemodynamic and physiologic changes, the review reveals pregnancy:

• Decreases systemic vascular resistance
• Increases heart rate
• Increases cardiac output
• Decreases deep venous blood flow
• Increases deep vein diameters, and
• Induces a hypercoagulable state

Treatment strategies for primary CVI in pregnancy, which occurs in up to 80% of women, were reviewed and include indications for non-pharmacologic therapies (compression, reflexology, water emersion), and pharmacologic treatments (non-steroidal anti-inflammatory drugs, fondaparinux, and low-molecular-weight heparin).

With an incidence up to 7 per 1,000 pregnancies, acute VTE remains an important issue in pregnancy.  The authors provided a thorough review of VTE prevention during pregnancy, and VTE treatment during pregnancy (including indications for caval filters and management of iliofemoral thrombosis).

“It is important for physicians to comprehend the full extent of the hemodynamic factors that contribute to the increased risk of lower extremity venous disease as well as the most appropriate and effective evidence-based management options,” stated Dr. Heller.  “While prophylaxis and treatment of VTE has been extensively studied in pregnancy, further research is required to look at the potential effectiveness and long-term safety profiles of new oral anticoagulants in the mother and fetus.” 

She also hopes that future randomized trials will evaluate treatment strategies to relieve symptoms associated with chronic venous insufficiency during pregnancy.

Complete understanding of these issues helps physicians prepare their patients for these eventualities during pregnancy and treat venous complications effectively. 

To download the complete article, open access through April 30, click here.  

Physicians should consider prescribing high-dose angiotensin inhibitors for patients with chronic limb-threatening ischemia (CLTI), a recent study from Harvard University suggests.

The report was published in the March edition of the Journal of Vascular Surgery by researchers from the Division of Vascular and Endovascular Surgery from the Beth Israel Deaconess Medical Center led by vascular surgeon Dr. Marc Schermerhorn.

The team conducted a retrospective review of 1,161 patients between 2005 and 2014 and evaluated the effect of renin-angiotensin system (RAS) inhibition on mortality in patients undergoing revascularization (both endovascular and surgical bypass) for CLTI.

In this population, RAS inhibition resulted in: 
•    Reduced mortality (67% versus 54% survival at three years)
•    Lower 30-day myocardial infarction (1.6% versus 4.3%)
•    No difference in major adverse limb events, amputation, or reinterventions

“These benefits were restricted to those prescribed high-dose RAS inhibition, and not realized in those on lower doses,” noted first author Dr. Thomas Bodewes.  As such, the authors recommend that, “physicians should strive to maintain patients on high-dose RAS inhibition, provided that such doses are tolerated in terms of blood pressure.”
Patients with CLTI are heavily burdened with atherosclerosis, which affects nearly all important vascular beds, including the cerebral, coronary, peripheral, renal and mesenteric circulatory systems.
 
A growing body of evidence suggests that renin-angiotensin system (RAS) inhibition has multiple cardiovascular benefits including:
•    Blood pressure control
•    Decrease in preload and afterload
•    Stabilization of plaque
•    Inhibition of smooth muscle proliferation
•    Improved vascular endothelial function
•    Reduced ventricular hypertrophy
•    Enhanced fibrinolysis

Despite this evidence, questions remain. The authors note that this was a retrospective single institution review and despite adjustment for multiple variables, the association between RAS inhibitor use and long-term outcomes may be confounded by other factors including some that were unmeasured. 
There are relatively modest number of non-white patients, and actual use of the medications beyond hospital discharge among the study patients is unknown. There are potential side effects to the use of RAS inhibitors that providers must consider in the dosing of these medications. Larger confirmatory studies are needed to confirm these findings and strengthen the evidence.

ClIck here to read the full-article, which is free to non-subscribers until April 30.

Physicians should consider prescribing high-dose angiotensin inhibitors for patients with chronic limb-threatening ischemia (CLTI), a recent study from Harvard University suggests.

The report was published in the March edition of the Journal of Vascular Surgery by researchers from the Division of Vascular and Endovascular Surgery from the Beth Israel Deaconess Medical Center led by vascular surgeon Dr. Marc Schermerhorn.

The team conducted a retrospective review of 1,161 patients between 2005 and 2014 and evaluated the effect of renin-angiotensin system (RAS) inhibition on mortality in patients undergoing revascularization (both endovascular and surgical bypass) for CLTI.

In this population, RAS inhibition resulted in: 
•    Reduced mortality (67% versus 54% survival at three years)
•    Lower 30-day myocardial infarction (1.6% versus 4.3%)
•    No difference in major adverse limb events, amputation, or reinterventions

“These benefits were restricted to those prescribed high-dose RAS inhibition, and not realized in those on lower doses,” noted first author Dr. Thomas Bodewes.  As such, the authors recommend that, “physicians should strive to maintain patients on high-dose RAS inhibition, provided that such doses are tolerated in terms of blood pressure.”
Patients with CLTI are heavily burdened with atherosclerosis, which affects nearly all important vascular beds, including the cerebral, coronary, peripheral, renal and mesenteric circulatory systems.
 
A growing body of evidence suggests that renin-angiotensin system (RAS) inhibition has multiple cardiovascular benefits including:
•    Blood pressure control
•    Decrease in preload and afterload
•    Stabilization of plaque
•    Inhibition of smooth muscle proliferation
•    Improved vascular endothelial function
•    Reduced ventricular hypertrophy
•    Enhanced fibrinolysis

Despite this evidence, questions remain. The authors note that this was a retrospective single institution review and despite adjustment for multiple variables, the association between RAS inhibitor use and long-term outcomes may be confounded by other factors including some that were unmeasured. 
There are relatively modest number of non-white patients, and actual use of the medications beyond hospital discharge among the study patients is unknown. There are potential side effects to the use of RAS inhibitors that providers must consider in the dosing of these medications. Larger confirmatory studies are needed to confirm these findings and strengthen the evidence.

ClIck here to read the full-article, which is free to non-subscribers until April 30.

Physicians should consider prescribing high-dose angiotensin inhibitors for patients with chronic limb-threatening ischemia (CLTI), a recent study from Harvard University suggests.

The report was published in the March edition of the Journal of Vascular Surgery by researchers from the Division of Vascular and Endovascular Surgery from the Beth Israel Deaconess Medical Center led by vascular surgeon Dr. Marc Schermerhorn.

The team conducted a retrospective review of 1,161 patients between 2005 and 2014 and evaluated the effect of renin-angiotensin system (RAS) inhibition on mortality in patients undergoing revascularization (both endovascular and surgical bypass) for CLTI.

In this population, RAS inhibition resulted in: 
•    Reduced mortality (67% versus 54% survival at three years)
•    Lower 30-day myocardial infarction (1.6% versus 4.3%)
•    No difference in major adverse limb events, amputation, or reinterventions

“These benefits were restricted to those prescribed high-dose RAS inhibition, and not realized in those on lower doses,” noted first author Dr. Thomas Bodewes.  As such, the authors recommend that, “physicians should strive to maintain patients on high-dose RAS inhibition, provided that such doses are tolerated in terms of blood pressure.”
Patients with CLTI are heavily burdened with atherosclerosis, which affects nearly all important vascular beds, including the cerebral, coronary, peripheral, renal and mesenteric circulatory systems.
 
A growing body of evidence suggests that renin-angiotensin system (RAS) inhibition has multiple cardiovascular benefits including:
•    Blood pressure control
•    Decrease in preload and afterload
•    Stabilization of plaque
•    Inhibition of smooth muscle proliferation
•    Improved vascular endothelial function
•    Reduced ventricular hypertrophy
•    Enhanced fibrinolysis

Despite this evidence, questions remain. The authors note that this was a retrospective single institution review and despite adjustment for multiple variables, the association between RAS inhibitor use and long-term outcomes may be confounded by other factors including some that were unmeasured. 
There are relatively modest number of non-white patients, and actual use of the medications beyond hospital discharge among the study patients is unknown. There are potential side effects to the use of RAS inhibitors that providers must consider in the dosing of these medications. Larger confirmatory studies are needed to confirm these findings and strengthen the evidence.

ClIck here to read the full-article, which is free to non-subscribers until April 30.

The Society of Hospital Medicine (SHM) has historically focused on meeting the needs of individual members of the hospital medicine team. Further investigation, however, revealed that the Society had members who were program directors, C-suite executives, multisite group leaders, and practice administrators who had more strategic needs, and SHM wanted to offer solutions that would also positively impact their staff.

One year ago, SHM launched a “listening tour” to gain an understanding of what some of these strategic objectives were and how the society might be able to assist. Representatives from SHM staff met with full teams from hospital systems as well as management companies and identified some common themes, including:

• Integrating nurse practitioners/physician assistants into their practices.
• Planning for growth and succession and incorporating SHM meetings, CME, and training into those plans.
• Proving the value of the hospital medicine program to the C-suite.

Why is Adfinitas Health choosing to become an institutional partner with SHM?

Adfinitas Health is a trusted partner to more than 50 diverse hospitals and post-acute facilities across Maryland, Virginia, Michigan, and Pennsylvania. We are mission focused and led by our core values, which means we always lead with a patient-centered approach to care that produces higher patient satisfaction, better clinical outcomes, and greater value for our partners. We focus on bringing leading-edge practices and protocols to our partner facilities to drive quality and elevate care.

Our decision to become an institutional partner with SHM was simple. Besides being the voice of our industry, SHM plays a critical role in advancing the field of hospital medicine. We know that our providers look to SHM as a resource for clinical and professional development; by becoming an institutional partner, we hope to support that growth objective.

We are looking forward to the opportunity to advance the field of hospital medicine and drive practices and innovations that better support patient-centered care.
 

Which SHM resources and opportunities do you find most valuable for your providers?

The most valuable resources for our providers are the opportunities for learning and professional development. The education offerings are comprehensive and evidence based, which is critical. Whether a provider is looking to fulfill a continuing medical education requirement or needs information to help enhance their performance, we know that they will get what they need from SHM.

The annual conferences, chapter events, and training academies also are valuable to our company and providers. We provide core hospitalist programs that can be customized with integrated complementary services – such as palliative care, pain management, pediatrics, and critical care – based on the needs of the client. We also heavily integrate advance practice providers into our programs. Therefore, we rely on the diverse set of training and learning opportunities that SHM holds throughout the year.

What does it mean to your organization to be the first partner in this program?

Adfinitas cofounders Doug Mitchell, MD, and Hung Davis, MD, have been committed to advancing the field of hospital medicine for nearly 2 decades. They were early members of SHM, along with our other company partners and many of our providers. So, it is an honor to be the first institutional partner – certainly an important milestone in our corporate history. The company has grown from 1 hospital in 2007 to more than 50 hospital and post-acute partners across four states over the past 11 years.

What long-term benefits do you see this partnership offering to your hospitalists?

At our size and scale, the need for a more formal institutional partnership with SHM made perfect sense. We strive to be an employer of choice for hospitalists, including physicians, nurse practitioners, and physician assistants. Our focus on core values builds a culture of engaged, talented employees who feel supported as they progress in their careers. We strive to do all we can to support that growth, and this partnership will help us meet and exceed that goal.

What message are you sending Adfinitas Health hospitalists by partnering with SHM?

We are encouraging our hospitalists to take full advantage of the many learning opportunities and resources that this partnership will bring to bear. We will be actively promoting the customized training that we’ll be offering, as well as the ease of accessing content through the online SHM Learning Portal.

In addition, we want our hospitalists to be connected to the field and remain on the cutting edge of what is important and how best to care for patients. We’ll be encouraging them to be active and involved members at the state and national levels and leverage SHM to grow their professional network.

For more information on SHM’s institutional partnerships, please contact Debra Beach, SHM customer experience manager, at 267-702-2644 or [email protected].
 

The Society of Hospital Medicine (SHM) has historically focused on meeting the needs of individual members of the hospital medicine team. Further investigation, however, revealed that the Society had members who were program directors, C-suite executives, multisite group leaders, and practice administrators who had more strategic needs, and SHM wanted to offer solutions that would also positively impact their staff.

One year ago, SHM launched a “listening tour” to gain an understanding of what some of these strategic objectives were and how the society might be able to assist. Representatives from SHM staff met with full teams from hospital systems as well as management companies and identified some common themes, including:

• Integrating nurse practitioners/physician assistants into their practices.
• Planning for growth and succession and incorporating SHM meetings, CME, and training into those plans.
• Proving the value of the hospital medicine program to the C-suite.

Why is Adfinitas Health choosing to become an institutional partner with SHM?

Adfinitas Health is a trusted partner to more than 50 diverse hospitals and post-acute facilities across Maryland, Virginia, Michigan, and Pennsylvania. We are mission focused and led by our core values, which means we always lead with a patient-centered approach to care that produces higher patient satisfaction, better clinical outcomes, and greater value for our partners. We focus on bringing leading-edge practices and protocols to our partner facilities to drive quality and elevate care.

Our decision to become an institutional partner with SHM was simple. Besides being the voice of our industry, SHM plays a critical role in advancing the field of hospital medicine. We know that our providers look to SHM as a resource for clinical and professional development; by becoming an institutional partner, we hope to support that growth objective.

We are looking forward to the opportunity to advance the field of hospital medicine and drive practices and innovations that better support patient-centered care.
 

Which SHM resources and opportunities do you find most valuable for your providers?

The most valuable resources for our providers are the opportunities for learning and professional development. The education offerings are comprehensive and evidence based, which is critical. Whether a provider is looking to fulfill a continuing medical education requirement or needs information to help enhance their performance, we know that they will get what they need from SHM.

The annual conferences, chapter events, and training academies also are valuable to our company and providers. We provide core hospitalist programs that can be customized with integrated complementary services – such as palliative care, pain management, pediatrics, and critical care – based on the needs of the client. We also heavily integrate advance practice providers into our programs. Therefore, we rely on the diverse set of training and learning opportunities that SHM holds throughout the year.

What does it mean to your organization to be the first partner in this program?

Adfinitas cofounders Doug Mitchell, MD, and Hung Davis, MD, have been committed to advancing the field of hospital medicine for nearly 2 decades. They were early members of SHM, along with our other company partners and many of our providers. So, it is an honor to be the first institutional partner – certainly an important milestone in our corporate history. The company has grown from 1 hospital in 2007 to more than 50 hospital and post-acute partners across four states over the past 11 years.

What long-term benefits do you see this partnership offering to your hospitalists?

At our size and scale, the need for a more formal institutional partnership with SHM made perfect sense. We strive to be an employer of choice for hospitalists, including physicians, nurse practitioners, and physician assistants. Our focus on core values builds a culture of engaged, talented employees who feel supported as they progress in their careers. We strive to do all we can to support that growth, and this partnership will help us meet and exceed that goal.

What message are you sending Adfinitas Health hospitalists by partnering with SHM?

We are encouraging our hospitalists to take full advantage of the many learning opportunities and resources that this partnership will bring to bear. We will be actively promoting the customized training that we’ll be offering, as well as the ease of accessing content through the online SHM Learning Portal.

In addition, we want our hospitalists to be connected to the field and remain on the cutting edge of what is important and how best to care for patients. We’ll be encouraging them to be active and involved members at the state and national levels and leverage SHM to grow their professional network.

For more information on SHM’s institutional partnerships, please contact Debra Beach, SHM customer experience manager, at 267-702-2644 or [email protected].
 

The Society of Hospital Medicine (SHM) has historically focused on meeting the needs of individual members of the hospital medicine team. Further investigation, however, revealed that the Society had members who were program directors, C-suite executives, multisite group leaders, and practice administrators who had more strategic needs, and SHM wanted to offer solutions that would also positively impact their staff.

One year ago, SHM launched a “listening tour” to gain an understanding of what some of these strategic objectives were and how the society might be able to assist. Representatives from SHM staff met with full teams from hospital systems as well as management companies and identified some common themes, including:

• Integrating nurse practitioners/physician assistants into their practices.
• Planning for growth and succession and incorporating SHM meetings, CME, and training into those plans.
• Proving the value of the hospital medicine program to the C-suite.

Why is Adfinitas Health choosing to become an institutional partner with SHM?

Adfinitas Health is a trusted partner to more than 50 diverse hospitals and post-acute facilities across Maryland, Virginia, Michigan, and Pennsylvania. We are mission focused and led by our core values, which means we always lead with a patient-centered approach to care that produces higher patient satisfaction, better clinical outcomes, and greater value for our partners. We focus on bringing leading-edge practices and protocols to our partner facilities to drive quality and elevate care.

Our decision to become an institutional partner with SHM was simple. Besides being the voice of our industry, SHM plays a critical role in advancing the field of hospital medicine. We know that our providers look to SHM as a resource for clinical and professional development; by becoming an institutional partner, we hope to support that growth objective.

We are looking forward to the opportunity to advance the field of hospital medicine and drive practices and innovations that better support patient-centered care.
 

Which SHM resources and opportunities do you find most valuable for your providers?

The most valuable resources for our providers are the opportunities for learning and professional development. The education offerings are comprehensive and evidence based, which is critical. Whether a provider is looking to fulfill a continuing medical education requirement or needs information to help enhance their performance, we know that they will get what they need from SHM.

The annual conferences, chapter events, and training academies also are valuable to our company and providers. We provide core hospitalist programs that can be customized with integrated complementary services – such as palliative care, pain management, pediatrics, and critical care – based on the needs of the client. We also heavily integrate advance practice providers into our programs. Therefore, we rely on the diverse set of training and learning opportunities that SHM holds throughout the year.

What does it mean to your organization to be the first partner in this program?

Adfinitas cofounders Doug Mitchell, MD, and Hung Davis, MD, have been committed to advancing the field of hospital medicine for nearly 2 decades. They were early members of SHM, along with our other company partners and many of our providers. So, it is an honor to be the first institutional partner – certainly an important milestone in our corporate history. The company has grown from 1 hospital in 2007 to more than 50 hospital and post-acute partners across four states over the past 11 years.

What long-term benefits do you see this partnership offering to your hospitalists?

At our size and scale, the need for a more formal institutional partnership with SHM made perfect sense. We strive to be an employer of choice for hospitalists, including physicians, nurse practitioners, and physician assistants. Our focus on core values builds a culture of engaged, talented employees who feel supported as they progress in their careers. We strive to do all we can to support that growth, and this partnership will help us meet and exceed that goal.

What message are you sending Adfinitas Health hospitalists by partnering with SHM?

We are encouraging our hospitalists to take full advantage of the many learning opportunities and resources that this partnership will bring to bear. We will be actively promoting the customized training that we’ll be offering, as well as the ease of accessing content through the online SHM Learning Portal.

In addition, we want our hospitalists to be connected to the field and remain on the cutting edge of what is important and how best to care for patients. We’ll be encouraging them to be active and involved members at the state and national levels and leverage SHM to grow their professional network.

For more information on SHM’s institutional partnerships, please contact Debra Beach, SHM customer experience manager, at 267-702-2644 or [email protected].
 

SILVER SPRING, MD. – In an effort to better match the vaccine to the virus, federal advisors have recommended two new strains be swapped into the 2018-2019 quadrivalent influenza vaccine.

The updates should be the influenza A(H3N2) component and the influenza B components.

Singapore A(H3N2) and the B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage) are recommended be added to A/Michigan/45/2015 (H1N1)pdm09-like virus and B/Phuket/3073/2013-like virus (B/Yamagata/16/88 lineage) for the upcoming season, according to a near-unanimous vote at a meeting of the Food and Drug Administration Vaccines and Related Biological Products Advisory Committee.

Trivalent vaccines should include the same strains, with the exception of B/Phuket/3073/2013-like virus (B/Yamagata/16/88 lineage), the committee recommended.

The panel voted separately on the strains, and all votes were unanimous, except for the vote on the B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage) in the trivalent vaccine, which was supported with 11 positive votes with 1 abstention.

[email protected]

SILVER SPRING, MD. – In an effort to better match the vaccine to the virus, federal advisors have recommended two new strains be swapped into the 2018-2019 quadrivalent influenza vaccine.

The updates should be the influenza A(H3N2) component and the influenza B components.

Singapore A(H3N2) and the B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage) are recommended be added to A/Michigan/45/2015 (H1N1)pdm09-like virus and B/Phuket/3073/2013-like virus (B/Yamagata/16/88 lineage) for the upcoming season, according to a near-unanimous vote at a meeting of the Food and Drug Administration Vaccines and Related Biological Products Advisory Committee.

Trivalent vaccines should include the same strains, with the exception of B/Phuket/3073/2013-like virus (B/Yamagata/16/88 lineage), the committee recommended.

The panel voted separately on the strains, and all votes were unanimous, except for the vote on the B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage) in the trivalent vaccine, which was supported with 11 positive votes with 1 abstention.

[email protected]

SILVER SPRING, MD. – In an effort to better match the vaccine to the virus, federal advisors have recommended two new strains be swapped into the 2018-2019 quadrivalent influenza vaccine.

The updates should be the influenza A(H3N2) component and the influenza B components.

Singapore A(H3N2) and the B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage) are recommended be added to A/Michigan/45/2015 (H1N1)pdm09-like virus and B/Phuket/3073/2013-like virus (B/Yamagata/16/88 lineage) for the upcoming season, according to a near-unanimous vote at a meeting of the Food and Drug Administration Vaccines and Related Biological Products Advisory Committee.

Trivalent vaccines should include the same strains, with the exception of B/Phuket/3073/2013-like virus (B/Yamagata/16/88 lineage), the committee recommended.

The panel voted separately on the strains, and all votes were unanimous, except for the vote on the B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage) in the trivalent vaccine, which was supported with 11 positive votes with 1 abstention.

[email protected]

ANAHEIM, CALIF. – Patients with heart disease can safely be reassured that sexual intercourse as a trigger for sudden cardiac death is extremely rare, Aapo Aro, MD, said at the American Heart Association scientific sessions.

He presented an analysis from the ongoing Oregon Sudden Unexpected Death Study, a population-based case-control study that captures all cases of sudden cardiac arrest (SCA) in the Portland, Ore., area.

This was the first-ever study to examine the burden of SCA triggered by sexual activity. Of 4,557 adjudicated cases of SCA in adults during 2002-2015, a mere 34, or 0.7%, happened during or within 1 hour of sexual intercourse.

Thirty-two of the 34 cases occurred in men. That works out to 1% of SCAs in men being related to sexual activity. In women, the rate was 10-fold lower, at 0.1%, noted Dr. Aro, a cardiologist at Helsinki University Hospital who was at Cedars-Sinai Medical Center in Los Angeles at the time he conducted this research.

Many of the Oregonians who experienced SCA had known heart disease at the time, regardless of whether the event occurred during sexual activity or at another time. Of note, however, SCA during sexual activity presented with ventricular fibrillation/ventricular tachycardia in 76% of cases, versus a 45% rate in individuals whose SCA was not associated with sexual intercourse.

“The data are very reassuring,” Dr. Aro said in an interview. “Many of these patients had known cardiac disease, but still the absolute numbers of events are very small. Our take home message from this study is that sexual activity can be regarded as safe even in cardiac patients.”

The Oregon Sudden Unexpected Death Study is funded by the National Heart, Lung, and Blood Institute and the American Heart Association. Dr. Aro reported having no financial conflicts of interest.

[email protected]

ANAHEIM, CALIF. – Patients with heart disease can safely be reassured that sexual intercourse as a trigger for sudden cardiac death is extremely rare, Aapo Aro, MD, said at the American Heart Association scientific sessions.

He presented an analysis from the ongoing Oregon Sudden Unexpected Death Study, a population-based case-control study that captures all cases of sudden cardiac arrest (SCA) in the Portland, Ore., area.

This was the first-ever study to examine the burden of SCA triggered by sexual activity. Of 4,557 adjudicated cases of SCA in adults during 2002-2015, a mere 34, or 0.7%, happened during or within 1 hour of sexual intercourse.

Thirty-two of the 34 cases occurred in men. That works out to 1% of SCAs in men being related to sexual activity. In women, the rate was 10-fold lower, at 0.1%, noted Dr. Aro, a cardiologist at Helsinki University Hospital who was at Cedars-Sinai Medical Center in Los Angeles at the time he conducted this research.

Many of the Oregonians who experienced SCA had known heart disease at the time, regardless of whether the event occurred during sexual activity or at another time. Of note, however, SCA during sexual activity presented with ventricular fibrillation/ventricular tachycardia in 76% of cases, versus a 45% rate in individuals whose SCA was not associated with sexual intercourse.

“The data are very reassuring,” Dr. Aro said in an interview. “Many of these patients had known cardiac disease, but still the absolute numbers of events are very small. Our take home message from this study is that sexual activity can be regarded as safe even in cardiac patients.”

The Oregon Sudden Unexpected Death Study is funded by the National Heart, Lung, and Blood Institute and the American Heart Association. Dr. Aro reported having no financial conflicts of interest.

[email protected]

ANAHEIM, CALIF. – Patients with heart disease can safely be reassured that sexual intercourse as a trigger for sudden cardiac death is extremely rare, Aapo Aro, MD, said at the American Heart Association scientific sessions.

He presented an analysis from the ongoing Oregon Sudden Unexpected Death Study, a population-based case-control study that captures all cases of sudden cardiac arrest (SCA) in the Portland, Ore., area.

This was the first-ever study to examine the burden of SCA triggered by sexual activity. Of 4,557 adjudicated cases of SCA in adults during 2002-2015, a mere 34, or 0.7%, happened during or within 1 hour of sexual intercourse.

Thirty-two of the 34 cases occurred in men. That works out to 1% of SCAs in men being related to sexual activity. In women, the rate was 10-fold lower, at 0.1%, noted Dr. Aro, a cardiologist at Helsinki University Hospital who was at Cedars-Sinai Medical Center in Los Angeles at the time he conducted this research.

Many of the Oregonians who experienced SCA had known heart disease at the time, regardless of whether the event occurred during sexual activity or at another time. Of note, however, SCA during sexual activity presented with ventricular fibrillation/ventricular tachycardia in 76% of cases, versus a 45% rate in individuals whose SCA was not associated with sexual intercourse.

“The data are very reassuring,” Dr. Aro said in an interview. “Many of these patients had known cardiac disease, but still the absolute numbers of events are very small. Our take home message from this study is that sexual activity can be regarded as safe even in cardiac patients.”

The Oregon Sudden Unexpected Death Study is funded by the National Heart, Lung, and Blood Institute and the American Heart Association. Dr. Aro reported having no financial conflicts of interest.

[email protected]

KAUAI, HAWAII – A topical halobetasol/tazarotene fixed-combination lotion for moderate to severe psoriasis hit all of its efficacy and safety endpoints in two phase 3 randomized, double-blind, multicenter clinical trials, Linda Stein Gold, MD, reported at the Hawaii Dermatology Seminar provided by the Global Academy for Medical Education/Skin Disease Education Foundation.

The fixed combination of halobetasol 0.01%/tazarotene 0.045% lotion takes advantage of an observation made 20 years ago: When tazarotene is combined with a potent topical corticosteroid, therapeutic efficacy is amplified synergistically while the problematic local side effects of each agent are diminished, explained Dr. Stein Gold, director of dermatology research at the Henry Ford Health System, Detroit.

Bruce Jancin/Frontline Medical News

[email protected]

KAUAI, HAWAII – A topical halobetasol/tazarotene fixed-combination lotion for moderate to severe psoriasis hit all of its efficacy and safety endpoints in two phase 3 randomized, double-blind, multicenter clinical trials, Linda Stein Gold, MD, reported at the Hawaii Dermatology Seminar provided by the Global Academy for Medical Education/Skin Disease Education Foundation.

The fixed combination of halobetasol 0.01%/tazarotene 0.045% lotion takes advantage of an observation made 20 years ago: When tazarotene is combined with a potent topical corticosteroid, therapeutic efficacy is amplified synergistically while the problematic local side effects of each agent are diminished, explained Dr. Stein Gold, director of dermatology research at the Henry Ford Health System, Detroit.

Bruce Jancin/Frontline Medical News

[email protected]

KAUAI, HAWAII – A topical halobetasol/tazarotene fixed-combination lotion for moderate to severe psoriasis hit all of its efficacy and safety endpoints in two phase 3 randomized, double-blind, multicenter clinical trials, Linda Stein Gold, MD, reported at the Hawaii Dermatology Seminar provided by the Global Academy for Medical Education/Skin Disease Education Foundation.

The fixed combination of halobetasol 0.01%/tazarotene 0.045% lotion takes advantage of an observation made 20 years ago: When tazarotene is combined with a potent topical corticosteroid, therapeutic efficacy is amplified synergistically while the problematic local side effects of each agent are diminished, explained Dr. Stein Gold, director of dermatology research at the Henry Ford Health System, Detroit.

Bruce Jancin/Frontline Medical News

[email protected]

Henry Ng, MD, MPH, an internal medicine physician and pediatrician in Cleveland who specializes in the treatment of lesbian, gay, bisexual, and transgender (LGBT) patients, walked into an exam room to meet a patient several years ago. The patient was 65 years old and presented as a man.

“I made an assumption about this person based on the cues that I saw and I misperceived this person’s identity,” he said. “A patient less comfortable in their skin may have left. And a younger patient would likely have been offended if I had met and misgendered them.”

If Dr. Ng could make this kind of error, it’s clear how easy it is for clinicians with less training and experience to make clumsy assumptions about gender identity.

Even with wider societal awareness of gender identity issues, the cultural sensibilities and training among hospitalists and other clinicians required for quality care of transgender patients is still lacking, Dr. Ng said. Unfortunately, many physicians may have little interest in providing this care, or lack the skills for it, he said.

In the hospital, patients already feel vulnerable because of their medical conditions, and treating transgender inpatients may require additional layers of complexity, experts say. For instance, how should a physician address a patient? The initial encounter can have a huge impact on the clinician’s ability to earn the patient’s trust, and sets the tone for the entire hospital stay. Which bathroom should a transgender patient use? What unique family issues must clinicians be aware of? Transgender patients may be more likely to have simmering tensions with immediate and extended family, and may not want certain family members involved in medical decisions.

Physicians and nurses must be aware of these issues to create a welcoming and logistically sound environment, said Nicole Rosendale, MD, a neurohospitalist at the University of California San Francisco who has a special interest in LGBT care.

Need for more training

Hospitalists will increasingly find themselves caring for transgender patients, as more people openly claim a gender identity outside the traditional gender categories. A recent study in the United Kingdom found that 20%-25% of people under 25 did not identify as heterosexual, or considered themselves as having a personal gender identity that did not correspond with the sex assigned at birth, Dr. Ng said.

“I don’t think this is something that is a trend, I don’t think it’s a fad,” Dr. Ng said. “I don’t think it’s going to go away.”

The amount of resources available for training clinicians in caring for transgender patients is expanding, he said, and both trainees and veteran clinicians can find educational programs tailored to their needs, although they might have to seek them out. Nonetheless, Dr. Ng thinks hospitalists would be wise to pursue such training.

Unfortunately, most medical schools do not as yet offer targeted training in transgender care, or even LGBT care more broadly, said Vin Tangpricha, MD, PhD, president elect of the World Professional Association for Transgender Health (WPATH).

“The biggest gap is training in medical school and residency,” Dr. Tangpricha said. “Only one out of three medical schools have any transgender curriculum taught to students. Physicians lack knowledge on the diagnosis of gender dysphoria and the hormone regimens that are commonly used. Also, physicians don’t feel comfortable speaking to transgender patients because they lack experience working with this population.”

Training in caring for transgender patients and other segments of the LGBT patient population is available through WPATH, the Fenway Institute in Boston, and GLMA, formerly known as the Gay & Lesbian Medical Association, as well some other organizations, Dr. Tangpricha said.

Dr. Rosendale took training into her own hands. She saw gaps in the curriculum, and started LGBT training programs at New York University, where she went to medical school, and at UCSF, where she completed her neurology residency and neurohospitalist fellowship.

The curriculum, which was blended with diversity training at UCSF, involved basic concepts such as terminology, the difference between gender identity and sexual orientation, communication tips, and discussions of the health care experience from the LGBT patient perspective. Even a relatively small amount of training can go a long way, she said.

“When I work with trainees now who have heard some of the lectures and have gone through some of the training, their fluency and their comfort with the terminology, with the concepts that are used within the LGBT community, is much better than it was before,” Dr. Rosendale said.

Demonstrating the importance of training to those in charge of curriculum decisions is the most important step for anyone interested in adding instruction for transgender care at their centers, she said.

Katie Imborek, MD, cofounder of the University of Iowa LGBTQ Clinic, has worked with hospitalists on improving their care for transgender patients. She and internal medicine physician Nicole Nisly, MD, opened the clinic when a need became apparent.

Before the University of Iowa clinic opened, a transgender advocacy group hosted a forum on LGBT health care, at which patients shared stories of frustration. One patient related a story about calling a department at the university, only to be told, “We don’t take care of people like you.” In another frustrating case, a transgender man had been having vaginal bleeding and called the obstetrics department seeking help. He was repeatedly told he was calling the wrong place. During a white board exercise at the forum, one patient drew buildings representing the university health care system surrounded by barbed wire, symbolizing an off-putting atmosphere in the emergency department that was rife with misgendering of patients.

Henry Ng, MD, MPH, an internal medicine physician and pediatrician in Cleveland who specializes in the treatment of lesbian, gay, bisexual, and transgender (LGBT) patients, walked into an exam room to meet a patient several years ago. The patient was 65 years old and presented as a man.

“I made an assumption about this person based on the cues that I saw and I misperceived this person’s identity,” he said. “A patient less comfortable in their skin may have left. And a younger patient would likely have been offended if I had met and misgendered them.”

If Dr. Ng could make this kind of error, it’s clear how easy it is for clinicians with less training and experience to make clumsy assumptions about gender identity.

Even with wider societal awareness of gender identity issues, the cultural sensibilities and training among hospitalists and other clinicians required for quality care of transgender patients is still lacking, Dr. Ng said. Unfortunately, many physicians may have little interest in providing this care, or lack the skills for it, he said.

In the hospital, patients already feel vulnerable because of their medical conditions, and treating transgender inpatients may require additional layers of complexity, experts say. For instance, how should a physician address a patient? The initial encounter can have a huge impact on the clinician’s ability to earn the patient’s trust, and sets the tone for the entire hospital stay. Which bathroom should a transgender patient use? What unique family issues must clinicians be aware of? Transgender patients may be more likely to have simmering tensions with immediate and extended family, and may not want certain family members involved in medical decisions.

Physicians and nurses must be aware of these issues to create a welcoming and logistically sound environment, said Nicole Rosendale, MD, a neurohospitalist at the University of California San Francisco who has a special interest in LGBT care.

Need for more training

Hospitalists will increasingly find themselves caring for transgender patients, as more people openly claim a gender identity outside the traditional gender categories. A recent study in the United Kingdom found that 20%-25% of people under 25 did not identify as heterosexual, or considered themselves as having a personal gender identity that did not correspond with the sex assigned at birth, Dr. Ng said.

“I don’t think this is something that is a trend, I don’t think it’s a fad,” Dr. Ng said. “I don’t think it’s going to go away.”

The amount of resources available for training clinicians in caring for transgender patients is expanding, he said, and both trainees and veteran clinicians can find educational programs tailored to their needs, although they might have to seek them out. Nonetheless, Dr. Ng thinks hospitalists would be wise to pursue such training.

Unfortunately, most medical schools do not as yet offer targeted training in transgender care, or even LGBT care more broadly, said Vin Tangpricha, MD, PhD, president elect of the World Professional Association for Transgender Health (WPATH).

“The biggest gap is training in medical school and residency,” Dr. Tangpricha said. “Only one out of three medical schools have any transgender curriculum taught to students. Physicians lack knowledge on the diagnosis of gender dysphoria and the hormone regimens that are commonly used. Also, physicians don’t feel comfortable speaking to transgender patients because they lack experience working with this population.”

Training in caring for transgender patients and other segments of the LGBT patient population is available through WPATH, the Fenway Institute in Boston, and GLMA, formerly known as the Gay & Lesbian Medical Association, as well some other organizations, Dr. Tangpricha said.

Dr. Rosendale took training into her own hands. She saw gaps in the curriculum, and started LGBT training programs at New York University, where she went to medical school, and at UCSF, where she completed her neurology residency and neurohospitalist fellowship.

The curriculum, which was blended with diversity training at UCSF, involved basic concepts such as terminology, the difference between gender identity and sexual orientation, communication tips, and discussions of the health care experience from the LGBT patient perspective. Even a relatively small amount of training can go a long way, she said.

“When I work with trainees now who have heard some of the lectures and have gone through some of the training, their fluency and their comfort with the terminology, with the concepts that are used within the LGBT community, is much better than it was before,” Dr. Rosendale said.

Demonstrating the importance of training to those in charge of curriculum decisions is the most important step for anyone interested in adding instruction for transgender care at their centers, she said.

Katie Imborek, MD, cofounder of the University of Iowa LGBTQ Clinic, has worked with hospitalists on improving their care for transgender patients. She and internal medicine physician Nicole Nisly, MD, opened the clinic when a need became apparent.

Before the University of Iowa clinic opened, a transgender advocacy group hosted a forum on LGBT health care, at which patients shared stories of frustration. One patient related a story about calling a department at the university, only to be told, “We don’t take care of people like you.” In another frustrating case, a transgender man had been having vaginal bleeding and called the obstetrics department seeking help. He was repeatedly told he was calling the wrong place. During a white board exercise at the forum, one patient drew buildings representing the university health care system surrounded by barbed wire, symbolizing an off-putting atmosphere in the emergency department that was rife with misgendering of patients.

Henry Ng, MD, MPH, an internal medicine physician and pediatrician in Cleveland who specializes in the treatment of lesbian, gay, bisexual, and transgender (LGBT) patients, walked into an exam room to meet a patient several years ago. The patient was 65 years old and presented as a man.

“I made an assumption about this person based on the cues that I saw and I misperceived this person’s identity,” he said. “A patient less comfortable in their skin may have left. And a younger patient would likely have been offended if I had met and misgendered them.”

If Dr. Ng could make this kind of error, it’s clear how easy it is for clinicians with less training and experience to make clumsy assumptions about gender identity.

Even with wider societal awareness of gender identity issues, the cultural sensibilities and training among hospitalists and other clinicians required for quality care of transgender patients is still lacking, Dr. Ng said. Unfortunately, many physicians may have little interest in providing this care, or lack the skills for it, he said.

In the hospital, patients already feel vulnerable because of their medical conditions, and treating transgender inpatients may require additional layers of complexity, experts say. For instance, how should a physician address a patient? The initial encounter can have a huge impact on the clinician’s ability to earn the patient’s trust, and sets the tone for the entire hospital stay. Which bathroom should a transgender patient use? What unique family issues must clinicians be aware of? Transgender patients may be more likely to have simmering tensions with immediate and extended family, and may not want certain family members involved in medical decisions.

Physicians and nurses must be aware of these issues to create a welcoming and logistically sound environment, said Nicole Rosendale, MD, a neurohospitalist at the University of California San Francisco who has a special interest in LGBT care.

Need for more training

Hospitalists will increasingly find themselves caring for transgender patients, as more people openly claim a gender identity outside the traditional gender categories. A recent study in the United Kingdom found that 20%-25% of people under 25 did not identify as heterosexual, or considered themselves as having a personal gender identity that did not correspond with the sex assigned at birth, Dr. Ng said.

“I don’t think this is something that is a trend, I don’t think it’s a fad,” Dr. Ng said. “I don’t think it’s going to go away.”

The amount of resources available for training clinicians in caring for transgender patients is expanding, he said, and both trainees and veteran clinicians can find educational programs tailored to their needs, although they might have to seek them out. Nonetheless, Dr. Ng thinks hospitalists would be wise to pursue such training.

Unfortunately, most medical schools do not as yet offer targeted training in transgender care, or even LGBT care more broadly, said Vin Tangpricha, MD, PhD, president elect of the World Professional Association for Transgender Health (WPATH).

“The biggest gap is training in medical school and residency,” Dr. Tangpricha said. “Only one out of three medical schools have any transgender curriculum taught to students. Physicians lack knowledge on the diagnosis of gender dysphoria and the hormone regimens that are commonly used. Also, physicians don’t feel comfortable speaking to transgender patients because they lack experience working with this population.”

Training in caring for transgender patients and other segments of the LGBT patient population is available through WPATH, the Fenway Institute in Boston, and GLMA, formerly known as the Gay & Lesbian Medical Association, as well some other organizations, Dr. Tangpricha said.

Dr. Rosendale took training into her own hands. She saw gaps in the curriculum, and started LGBT training programs at New York University, where she went to medical school, and at UCSF, where she completed her neurology residency and neurohospitalist fellowship.

The curriculum, which was blended with diversity training at UCSF, involved basic concepts such as terminology, the difference between gender identity and sexual orientation, communication tips, and discussions of the health care experience from the LGBT patient perspective. Even a relatively small amount of training can go a long way, she said.

“When I work with trainees now who have heard some of the lectures and have gone through some of the training, their fluency and their comfort with the terminology, with the concepts that are used within the LGBT community, is much better than it was before,” Dr. Rosendale said.

Demonstrating the importance of training to those in charge of curriculum decisions is the most important step for anyone interested in adding instruction for transgender care at their centers, she said.

Katie Imborek, MD, cofounder of the University of Iowa LGBTQ Clinic, has worked with hospitalists on improving their care for transgender patients. She and internal medicine physician Nicole Nisly, MD, opened the clinic when a need became apparent.

Before the University of Iowa clinic opened, a transgender advocacy group hosted a forum on LGBT health care, at which patients shared stories of frustration. One patient related a story about calling a department at the university, only to be told, “We don’t take care of people like you.” In another frustrating case, a transgender man had been having vaginal bleeding and called the obstetrics department seeking help. He was repeatedly told he was calling the wrong place. During a white board exercise at the forum, one patient drew buildings representing the university health care system surrounded by barbed wire, symbolizing an off-putting atmosphere in the emergency department that was rife with misgendering of patients.

LAS VEGAS – On April 16, 2007, a 23-year-old man shot 32 people to death and injured 23 others during a massacre on the campus of Virginia Tech University in Blacksburg, before taking his own life. On the same day, 231 other gun casualties occurred in other areas of the United States, 83 of them fatal and 148 nonfatal, according to Jeffrey W. Swanson, PhD.

“These were domestic violence incidents, suicides, some unintentional injuries, and a few law enforcement actions,” he said at an annual psychopharmacology update held by the Nevada Psychiatric Association. “This is the daily drip, drip, drip of gun violence in our country.”

According to data from the Substance Abuse and Mental Health Services Administration, 9.8 million adults in the United States have a serious mental illness, 2.5 million have a co-occurring substance use disorder, 1.9 million have no insurance, 3.1 million go without treatment for their mental illness, 100,000 are homeless, and about 1 million find themselves in jail or in prison. “We probably have more people with a serious mental illness in one of our big-city jails every day than we ever had in the largest asylum in the middle of the 20th century,” said Dr. Swanson, professor of psychiatry and behavioral sciences at Duke University, Durham, N.C. “I think that’s scandalous. It probably costs our society $318 billion per year. On the other hand, we have gun-related violence that claims 36,000 lives each year. One economist estimates that costs our society $174 billion per year. Those are two different public health problems that come together on their edges.”

Doug Brunk/Frontline Medical News

• Prioritize contemporaneous risk assessment based on evidence of behaviors that correlate with violence and self-harm at specific times, not mental illness or treatment history per se as a category of exclusion.
• Preempt existing gun access, rather than simply thwarting a new gun purchase by a dangerous person.
• Provide legal due process for deprivation of gun rights.
• Preserve confidential therapeutic relationships. “You don’t want a crisis-driven law that requires doctors to report any patient who talks with them about suicide, because that can have a chilling effect and keep people away from seeking treatment, and also inhibit their disclosures in therapy,” he said.

Prevent the unpredictable through comprehensive background checks, but also by reducing the social determinant of violence and investing in improved access to mental health and substance abuse services.

“This is a complex puzzle, with maybe a couple of pieces hidden under the rug,” Dr. Swanson said.

He reported having no financial disclosures.

[email protected]

LAS VEGAS – On April 16, 2007, a 23-year-old man shot 32 people to death and injured 23 others during a massacre on the campus of Virginia Tech University in Blacksburg, before taking his own life. On the same day, 231 other gun casualties occurred in other areas of the United States, 83 of them fatal and 148 nonfatal, according to Jeffrey W. Swanson, PhD.

“These were domestic violence incidents, suicides, some unintentional injuries, and a few law enforcement actions,” he said at an annual psychopharmacology update held by the Nevada Psychiatric Association. “This is the daily drip, drip, drip of gun violence in our country.”

According to data from the Substance Abuse and Mental Health Services Administration, 9.8 million adults in the United States have a serious mental illness, 2.5 million have a co-occurring substance use disorder, 1.9 million have no insurance, 3.1 million go without treatment for their mental illness, 100,000 are homeless, and about 1 million find themselves in jail or in prison. “We probably have more people with a serious mental illness in one of our big-city jails every day than we ever had in the largest asylum in the middle of the 20th century,” said Dr. Swanson, professor of psychiatry and behavioral sciences at Duke University, Durham, N.C. “I think that’s scandalous. It probably costs our society $318 billion per year. On the other hand, we have gun-related violence that claims 36,000 lives each year. One economist estimates that costs our society $174 billion per year. Those are two different public health problems that come together on their edges.”

Doug Brunk/Frontline Medical News

• Prioritize contemporaneous risk assessment based on evidence of behaviors that correlate with violence and self-harm at specific times, not mental illness or treatment history per se as a category of exclusion.
• Preempt existing gun access, rather than simply thwarting a new gun purchase by a dangerous person.
• Provide legal due process for deprivation of gun rights.
• Preserve confidential therapeutic relationships. “You don’t want a crisis-driven law that requires doctors to report any patient who talks with them about suicide, because that can have a chilling effect and keep people away from seeking treatment, and also inhibit their disclosures in therapy,” he said.

Prevent the unpredictable through comprehensive background checks, but also by reducing the social determinant of violence and investing in improved access to mental health and substance abuse services.

“This is a complex puzzle, with maybe a couple of pieces hidden under the rug,” Dr. Swanson said.

He reported having no financial disclosures.

[email protected]

LAS VEGAS – On April 16, 2007, a 23-year-old man shot 32 people to death and injured 23 others during a massacre on the campus of Virginia Tech University in Blacksburg, before taking his own life. On the same day, 231 other gun casualties occurred in other areas of the United States, 83 of them fatal and 148 nonfatal, according to Jeffrey W. Swanson, PhD.

“These were domestic violence incidents, suicides, some unintentional injuries, and a few law enforcement actions,” he said at an annual psychopharmacology update held by the Nevada Psychiatric Association. “This is the daily drip, drip, drip of gun violence in our country.”

According to data from the Substance Abuse and Mental Health Services Administration, 9.8 million adults in the United States have a serious mental illness, 2.5 million have a co-occurring substance use disorder, 1.9 million have no insurance, 3.1 million go without treatment for their mental illness, 100,000 are homeless, and about 1 million find themselves in jail or in prison. “We probably have more people with a serious mental illness in one of our big-city jails every day than we ever had in the largest asylum in the middle of the 20th century,” said Dr. Swanson, professor of psychiatry and behavioral sciences at Duke University, Durham, N.C. “I think that’s scandalous. It probably costs our society $318 billion per year. On the other hand, we have gun-related violence that claims 36,000 lives each year. One economist estimates that costs our society $174 billion per year. Those are two different public health problems that come together on their edges.”

Doug Brunk/Frontline Medical News

• Prioritize contemporaneous risk assessment based on evidence of behaviors that correlate with violence and self-harm at specific times, not mental illness or treatment history per se as a category of exclusion.
• Preempt existing gun access, rather than simply thwarting a new gun purchase by a dangerous person.
• Provide legal due process for deprivation of gun rights.
• Preserve confidential therapeutic relationships. “You don’t want a crisis-driven law that requires doctors to report any patient who talks with them about suicide, because that can have a chilling effect and keep people away from seeking treatment, and also inhibit their disclosures in therapy,” he said.

Prevent the unpredictable through comprehensive background checks, but also by reducing the social determinant of violence and investing in improved access to mental health and substance abuse services.

“This is a complex puzzle, with maybe a couple of pieces hidden under the rug,” Dr. Swanson said.

He reported having no financial disclosures.

[email protected]

At 87, Maxine Stanich cared more about improving the quality of her life than prolonging it.

She suffered from a long list of health problems, including heart failure and chronic lung disease that could leave her gasping for breath.

When her time came, she wanted to die a natural death, Stanich told her daughter, and signed a “do not resuscitate” directive, or DNR, ordering doctors not to revive her should her heart stop.

Yet a trip to a San Francisco emergency room for shortness of breath in 2008 led Stanich to get a defibrillator implanted in her chest – a medical device to keep her alive by delivering a powerful shock. At the time, Stanich didn’t fully grasp what she had agreed to, even though she signed a document granting permission for the procedure, said her daughter, Susan Giaquinto.

That clarity came only during a subsequent visit to a different hospital, when a surprised ER doctor saw a defibrillator protruding from the DNR patient’s thin chest. To Stanich’s horror, the ER doctor explained that the device would not allow her to slip away painlessly and that the jolt would be “so strong that it will knock her across the room,” said Giaquinto, who accompanied her mother on both hospital trips.

Surgery like this has become all too common among those near the end of life, experts say. Nearly one in three Medicare patients undergo an operation in the year before they die, even though the evidence shows that many are more likely to be harmed than to benefit from it.

The practice is driven by financial incentives that reward doctors for doing procedures, as well as a medical culture in which patients and doctors are reluctant to talk about how surgical interventions should be prescribed more judiciously, said Rita Redberg, M.D., a cardiologist who treated Stanich when she sought care at the second hospital.

“We have a culture that believes in very aggressive care,” said Dr. Redberg, who at the University of California–San Francisco specializes in heart disease in women. “We are often not considering the chance of benefit and chance of harm, and how that changes when you get older. We also fail to have conversations about what patients value most.”

While surgery is typically lifesaving for younger people, operating on frail, older patients rarely helps them live longer or returns the quality of life they once enjoyed, according to a 2016 paper in Annals of Surgery.

The cost of these surgeries – typically paid for by Medicare, the government health insurance program for people over 65 – involve more than money, said Amber Barnato, MD, professor at the Dartmouth Institute for Health Policy and Clinical Practice. Older patients who undergo surgery within a year of death spent 50 percent more time in the hospital than others, and nearly twice as many days in intensive care.

And while some robust octogenarians have many years ahead of them, studies show that surgery is also common among those who are far more frail.

Eighteen percent of Medicare patients have surgery in their final month of life and 8% in their final week, according to a 2011 study in The Lancet.

More than 12% of defibrillators were implanted in people older than 80, according to a 2015 study. Doctors implant about 158,000 of the devices each year, according to the American College of Cardiology. The total cost of the procedure runs about $60,000.

Procedures performed in the elderly range from major operations that require lengthy recoveries to relatively minor surgery performed in a doctor’s office, such as the removal of nonfatal skin cancers, that would likely never cause any problems.

Research led by Eleni Linos, MD, has shown that people with limited life expectancies are treated for nonfatal skin cancers as aggressively as younger patients. Among patients with a nonfatal skin cancer and a limited time to live, 70 percent underwent surgery, according to her 2013 study in JAMA Internal Medicine.

When less is more

Surgery poses serious risks for older people, who weather anesthesia poorly and whose skin takes longer to heal. Among seniors who undergo urgent or emergency abdominal surgery, 20% die within 30 days, studies show.

With diminished mental acuity and an old-fashioned respect for the medical profession, some aging patients are vulnerable to unwanted interventions. Stanich agreed to a pacemaker simply because her doctor suggested it, Giaquinto said. Many people of Stanich’s generation “thought doctors were God … They never questioned doctors – ever.”

Margaret Schwarze, MD, a surgeon and associate professor at the University of Wisconsin, said that older patients often don’t feel the financial pain of surgery because insurance pays most of the cost.

When a surgeon offers to “fix” the heart valve in a person with multiple diseases, for example, the patient may assume that surgery will fix all of her medical problems, Dr. Schwarze said. “With older patients with lots of chronic illnesses, we’re not really fixing anything.”

Even as a doctor, Dr. Redberg said, she struggles to prevent other doctors from performing too many procedures on her 92-year-old mother, Mae, who lives in New York City.

Dr. Redberg said doctors recently treated her mother for melanoma – the most serious type of skin cancer. After the cancer was removed from her leg, Dr. Redberg’s mother was urged by a doctor to undergo an additional surgery to cut away more tissue and nearby lymph nodes, which can harbor cancerous cells.

“Every time she went in, the dermatologist wanted to refer her to a surgeon,” Dr. Redberg said. And “Medicare would have been happy to pay for it.”

But her mother often has problems with wounds healing, she said, and recovery would likely have taken 3 months. When Dr. Redberg pressed a surgeon about the benefits, he said the procedure could reduce the chances of cancer coming back within 3-5 years.

Dr. Redberg said her mother laughed and said, “I’m not interested in doing something that will help me in 3-5 years. I doubt I’ll be here.”

Finding solutions

The momentum of hospital care can make people feel as if they’re on a moving train and can’t jump off.

The rush of medical decisions “doesn’t allow time to deliberate or consider the patients’ overall health or what their goals and values might be,” said Jacqueline Kruser, MD, an instructor in pulmonary and critical care medicine and medical social sciences at the Northwestern University.

Many hospitals and health systems are developing “decision aids,” easy-to-understand written materials and videos to help patients make more informed medical decisions, giving them time to develop more realistic expectations.

After Kaiser Permanente Washington introduced the tools relating to joint replacement, the number of patients choosing to have hip replacement surgery fell 26%, while knee replacements declined 38%, according to a study in Health Affairs. (Kaiser Permanente is not affiliated with Kaiser Health News, which is an editorially independent program of the Kaiser Family Foundation.)

In a paper published last year in JAMA Surgery and the Journal of Pain and Symptom Management, Dr. Schwarze, Dr. Kruser and colleagues suggested creating narratives to illustrate surgical risks, rather than relying on statistics.

Instead of telling patients that surgery carries a 20% risk of stroke, for example, doctors should lay out the best, worst and most likely outcomes.

In the best-case scenario, a patient might spend weeks in the hospital after surgery, living the rest of her life in a nursing home. In the worst case, the same patient dies after several weeks in intensive care. In the most likely scenario, the patient survives just 2-3 months after surgery.

Dr. Schwarze said, “If someone says they can’t tolerate the best-case scenario – which involves them being in a nursing home – then maybe we shouldn’t be doing this.”

Maxine Stanich was admitted to the hospital after going to the ER because she felt short of breath. She experienced an abnormal heart rhythm in the procedure room during a cardiac test – not an unusual event during a procedure in which a wire is threaded into the heart. Based on that, doctors decided to implant a pacemaker and defibrillator the next day.

Dr. Redberg was consulted when the patient objected to the device that was now embedded in her chest. She was “very alert. She was very clear about what she did and did not want done. She told me she didn’t want to be shocked,” Redberg said.

After Dr. Redberg deactivated the defibrillator, which can be reprogrammed remotely, Stanich was discharged, with home hospice service. With nothing more than her medicines, she survived another 2 years and 3 months, dying at home just after her 90th birthday in 2010.

Kaiser Health News is a nonprofit news service covering health issues. It is an editorially independent program of the Kaiser Family Foundation that is not affiliated with Kaiser Permanente. KHN’s coverage related to aging and improving care of older adults is supported in part by The John A. Hartford Foundation.

At 87, Maxine Stanich cared more about improving the quality of her life than prolonging it.

She suffered from a long list of health problems, including heart failure and chronic lung disease that could leave her gasping for breath.

When her time came, she wanted to die a natural death, Stanich told her daughter, and signed a “do not resuscitate” directive, or DNR, ordering doctors not to revive her should her heart stop.

Yet a trip to a San Francisco emergency room for shortness of breath in 2008 led Stanich to get a defibrillator implanted in her chest – a medical device to keep her alive by delivering a powerful shock. At the time, Stanich didn’t fully grasp what she had agreed to, even though she signed a document granting permission for the procedure, said her daughter, Susan Giaquinto.

That clarity came only during a subsequent visit to a different hospital, when a surprised ER doctor saw a defibrillator protruding from the DNR patient’s thin chest. To Stanich’s horror, the ER doctor explained that the device would not allow her to slip away painlessly and that the jolt would be “so strong that it will knock her across the room,” said Giaquinto, who accompanied her mother on both hospital trips.

Surgery like this has become all too common among those near the end of life, experts say. Nearly one in three Medicare patients undergo an operation in the year before they die, even though the evidence shows that many are more likely to be harmed than to benefit from it.

The practice is driven by financial incentives that reward doctors for doing procedures, as well as a medical culture in which patients and doctors are reluctant to talk about how surgical interventions should be prescribed more judiciously, said Rita Redberg, M.D., a cardiologist who treated Stanich when she sought care at the second hospital.

“We have a culture that believes in very aggressive care,” said Dr. Redberg, who at the University of California–San Francisco specializes in heart disease in women. “We are often not considering the chance of benefit and chance of harm, and how that changes when you get older. We also fail to have conversations about what patients value most.”

While surgery is typically lifesaving for younger people, operating on frail, older patients rarely helps them live longer or returns the quality of life they once enjoyed, according to a 2016 paper in Annals of Surgery.

The cost of these surgeries – typically paid for by Medicare, the government health insurance program for people over 65 – involve more than money, said Amber Barnato, MD, professor at the Dartmouth Institute for Health Policy and Clinical Practice. Older patients who undergo surgery within a year of death spent 50 percent more time in the hospital than others, and nearly twice as many days in intensive care.

And while some robust octogenarians have many years ahead of them, studies show that surgery is also common among those who are far more frail.

Eighteen percent of Medicare patients have surgery in their final month of life and 8% in their final week, according to a 2011 study in The Lancet.

More than 12% of defibrillators were implanted in people older than 80, according to a 2015 study. Doctors implant about 158,000 of the devices each year, according to the American College of Cardiology. The total cost of the procedure runs about $60,000.

Procedures performed in the elderly range from major operations that require lengthy recoveries to relatively minor surgery performed in a doctor’s office, such as the removal of nonfatal skin cancers, that would likely never cause any problems.

Research led by Eleni Linos, MD, has shown that people with limited life expectancies are treated for nonfatal skin cancers as aggressively as younger patients. Among patients with a nonfatal skin cancer and a limited time to live, 70 percent underwent surgery, according to her 2013 study in JAMA Internal Medicine.

When less is more

Surgery poses serious risks for older people, who weather anesthesia poorly and whose skin takes longer to heal. Among seniors who undergo urgent or emergency abdominal surgery, 20% die within 30 days, studies show.

With diminished mental acuity and an old-fashioned respect for the medical profession, some aging patients are vulnerable to unwanted interventions. Stanich agreed to a pacemaker simply because her doctor suggested it, Giaquinto said. Many people of Stanich’s generation “thought doctors were God … They never questioned doctors – ever.”

Margaret Schwarze, MD, a surgeon and associate professor at the University of Wisconsin, said that older patients often don’t feel the financial pain of surgery because insurance pays most of the cost.

When a surgeon offers to “fix” the heart valve in a person with multiple diseases, for example, the patient may assume that surgery will fix all of her medical problems, Dr. Schwarze said. “With older patients with lots of chronic illnesses, we’re not really fixing anything.”

Even as a doctor, Dr. Redberg said, she struggles to prevent other doctors from performing too many procedures on her 92-year-old mother, Mae, who lives in New York City.

Dr. Redberg said doctors recently treated her mother for melanoma – the most serious type of skin cancer. After the cancer was removed from her leg, Dr. Redberg’s mother was urged by a doctor to undergo an additional surgery to cut away more tissue and nearby lymph nodes, which can harbor cancerous cells.

“Every time she went in, the dermatologist wanted to refer her to a surgeon,” Dr. Redberg said. And “Medicare would have been happy to pay for it.”

But her mother often has problems with wounds healing, she said, and recovery would likely have taken 3 months. When Dr. Redberg pressed a surgeon about the benefits, he said the procedure could reduce the chances of cancer coming back within 3-5 years.

Dr. Redberg said her mother laughed and said, “I’m not interested in doing something that will help me in 3-5 years. I doubt I’ll be here.”

Finding solutions

The momentum of hospital care can make people feel as if they’re on a moving train and can’t jump off.

The rush of medical decisions “doesn’t allow time to deliberate or consider the patients’ overall health or what their goals and values might be,” said Jacqueline Kruser, MD, an instructor in pulmonary and critical care medicine and medical social sciences at the Northwestern University.

Many hospitals and health systems are developing “decision aids,” easy-to-understand written materials and videos to help patients make more informed medical decisions, giving them time to develop more realistic expectations.

After Kaiser Permanente Washington introduced the tools relating to joint replacement, the number of patients choosing to have hip replacement surgery fell 26%, while knee replacements declined 38%, according to a study in Health Affairs. (Kaiser Permanente is not affiliated with Kaiser Health News, which is an editorially independent program of the Kaiser Family Foundation.)

In a paper published last year in JAMA Surgery and the Journal of Pain and Symptom Management, Dr. Schwarze, Dr. Kruser and colleagues suggested creating narratives to illustrate surgical risks, rather than relying on statistics.

Instead of telling patients that surgery carries a 20% risk of stroke, for example, doctors should lay out the best, worst and most likely outcomes.

In the best-case scenario, a patient might spend weeks in the hospital after surgery, living the rest of her life in a nursing home. In the worst case, the same patient dies after several weeks in intensive care. In the most likely scenario, the patient survives just 2-3 months after surgery.

Dr. Schwarze said, “If someone says they can’t tolerate the best-case scenario – which involves them being in a nursing home – then maybe we shouldn’t be doing this.”

Maxine Stanich was admitted to the hospital after going to the ER because she felt short of breath. She experienced an abnormal heart rhythm in the procedure room during a cardiac test – not an unusual event during a procedure in which a wire is threaded into the heart. Based on that, doctors decided to implant a pacemaker and defibrillator the next day.

Dr. Redberg was consulted when the patient objected to the device that was now embedded in her chest. She was “very alert. She was very clear about what she did and did not want done. She told me she didn’t want to be shocked,” Redberg said.

After Dr. Redberg deactivated the defibrillator, which can be reprogrammed remotely, Stanich was discharged, with home hospice service. With nothing more than her medicines, she survived another 2 years and 3 months, dying at home just after her 90th birthday in 2010.

Kaiser Health News is a nonprofit news service covering health issues. It is an editorially independent program of the Kaiser Family Foundation that is not affiliated with Kaiser Permanente. KHN’s coverage related to aging and improving care of older adults is supported in part by The John A. Hartford Foundation.

At 87, Maxine Stanich cared more about improving the quality of her life than prolonging it.

She suffered from a long list of health problems, including heart failure and chronic lung disease that could leave her gasping for breath.

When her time came, she wanted to die a natural death, Stanich told her daughter, and signed a “do not resuscitate” directive, or DNR, ordering doctors not to revive her should her heart stop.

Yet a trip to a San Francisco emergency room for shortness of breath in 2008 led Stanich to get a defibrillator implanted in her chest – a medical device to keep her alive by delivering a powerful shock. At the time, Stanich didn’t fully grasp what she had agreed to, even though she signed a document granting permission for the procedure, said her daughter, Susan Giaquinto.

That clarity came only during a subsequent visit to a different hospital, when a surprised ER doctor saw a defibrillator protruding from the DNR patient’s thin chest. To Stanich’s horror, the ER doctor explained that the device would not allow her to slip away painlessly and that the jolt would be “so strong that it will knock her across the room,” said Giaquinto, who accompanied her mother on both hospital trips.

Surgery like this has become all too common among those near the end of life, experts say. Nearly one in three Medicare patients undergo an operation in the year before they die, even though the evidence shows that many are more likely to be harmed than to benefit from it.

The practice is driven by financial incentives that reward doctors for doing procedures, as well as a medical culture in which patients and doctors are reluctant to talk about how surgical interventions should be prescribed more judiciously, said Rita Redberg, M.D., a cardiologist who treated Stanich when she sought care at the second hospital.

“We have a culture that believes in very aggressive care,” said Dr. Redberg, who at the University of California–San Francisco specializes in heart disease in women. “We are often not considering the chance of benefit and chance of harm, and how that changes when you get older. We also fail to have conversations about what patients value most.”

While surgery is typically lifesaving for younger people, operating on frail, older patients rarely helps them live longer or returns the quality of life they once enjoyed, according to a 2016 paper in Annals of Surgery.

The cost of these surgeries – typically paid for by Medicare, the government health insurance program for people over 65 – involve more than money, said Amber Barnato, MD, professor at the Dartmouth Institute for Health Policy and Clinical Practice. Older patients who undergo surgery within a year of death spent 50 percent more time in the hospital than others, and nearly twice as many days in intensive care.

And while some robust octogenarians have many years ahead of them, studies show that surgery is also common among those who are far more frail.

Eighteen percent of Medicare patients have surgery in their final month of life and 8% in their final week, according to a 2011 study in The Lancet.

More than 12% of defibrillators were implanted in people older than 80, according to a 2015 study. Doctors implant about 158,000 of the devices each year, according to the American College of Cardiology. The total cost of the procedure runs about $60,000.

Procedures performed in the elderly range from major operations that require lengthy recoveries to relatively minor surgery performed in a doctor’s office, such as the removal of nonfatal skin cancers, that would likely never cause any problems.

Research led by Eleni Linos, MD, has shown that people with limited life expectancies are treated for nonfatal skin cancers as aggressively as younger patients. Among patients with a nonfatal skin cancer and a limited time to live, 70 percent underwent surgery, according to her 2013 study in JAMA Internal Medicine.

When less is more

Surgery poses serious risks for older people, who weather anesthesia poorly and whose skin takes longer to heal. Among seniors who undergo urgent or emergency abdominal surgery, 20% die within 30 days, studies show.

With diminished mental acuity and an old-fashioned respect for the medical profession, some aging patients are vulnerable to unwanted interventions. Stanich agreed to a pacemaker simply because her doctor suggested it, Giaquinto said. Many people of Stanich’s generation “thought doctors were God … They never questioned doctors – ever.”

Margaret Schwarze, MD, a surgeon and associate professor at the University of Wisconsin, said that older patients often don’t feel the financial pain of surgery because insurance pays most of the cost.

When a surgeon offers to “fix” the heart valve in a person with multiple diseases, for example, the patient may assume that surgery will fix all of her medical problems, Dr. Schwarze said. “With older patients with lots of chronic illnesses, we’re not really fixing anything.”

Even as a doctor, Dr. Redberg said, she struggles to prevent other doctors from performing too many procedures on her 92-year-old mother, Mae, who lives in New York City.

Dr. Redberg said doctors recently treated her mother for melanoma – the most serious type of skin cancer. After the cancer was removed from her leg, Dr. Redberg’s mother was urged by a doctor to undergo an additional surgery to cut away more tissue and nearby lymph nodes, which can harbor cancerous cells.

“Every time she went in, the dermatologist wanted to refer her to a surgeon,” Dr. Redberg said. And “Medicare would have been happy to pay for it.”

But her mother often has problems with wounds healing, she said, and recovery would likely have taken 3 months. When Dr. Redberg pressed a surgeon about the benefits, he said the procedure could reduce the chances of cancer coming back within 3-5 years.

Dr. Redberg said her mother laughed and said, “I’m not interested in doing something that will help me in 3-5 years. I doubt I’ll be here.”

Finding solutions

The momentum of hospital care can make people feel as if they’re on a moving train and can’t jump off.

The rush of medical decisions “doesn’t allow time to deliberate or consider the patients’ overall health or what their goals and values might be,” said Jacqueline Kruser, MD, an instructor in pulmonary and critical care medicine and medical social sciences at the Northwestern University.

Many hospitals and health systems are developing “decision aids,” easy-to-understand written materials and videos to help patients make more informed medical decisions, giving them time to develop more realistic expectations.

After Kaiser Permanente Washington introduced the tools relating to joint replacement, the number of patients choosing to have hip replacement surgery fell 26%, while knee replacements declined 38%, according to a study in Health Affairs. (Kaiser Permanente is not affiliated with Kaiser Health News, which is an editorially independent program of the Kaiser Family Foundation.)

In a paper published last year in JAMA Surgery and the Journal of Pain and Symptom Management, Dr. Schwarze, Dr. Kruser and colleagues suggested creating narratives to illustrate surgical risks, rather than relying on statistics.

Instead of telling patients that surgery carries a 20% risk of stroke, for example, doctors should lay out the best, worst and most likely outcomes.

In the best-case scenario, a patient might spend weeks in the hospital after surgery, living the rest of her life in a nursing home. In the worst case, the same patient dies after several weeks in intensive care. In the most likely scenario, the patient survives just 2-3 months after surgery.

Dr. Schwarze said, “If someone says they can’t tolerate the best-case scenario – which involves them being in a nursing home – then maybe we shouldn’t be doing this.”

Maxine Stanich was admitted to the hospital after going to the ER because she felt short of breath. She experienced an abnormal heart rhythm in the procedure room during a cardiac test – not an unusual event during a procedure in which a wire is threaded into the heart. Based on that, doctors decided to implant a pacemaker and defibrillator the next day.

Dr. Redberg was consulted when the patient objected to the device that was now embedded in her chest. She was “very alert. She was very clear about what she did and did not want done. She told me she didn’t want to be shocked,” Redberg said.

After Dr. Redberg deactivated the defibrillator, which can be reprogrammed remotely, Stanich was discharged, with home hospice service. With nothing more than her medicines, she survived another 2 years and 3 months, dying at home just after her 90th birthday in 2010.

Kaiser Health News is a nonprofit news service covering health issues. It is an editorially independent program of the Kaiser Family Foundation that is not affiliated with Kaiser Permanente. KHN’s coverage related to aging and improving care of older adults is supported in part by The John A. Hartford Foundation.